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A B S T R A C T
Background
There is a substantial body of evidence that prescribing for care home residents is suboptimal and requires improvement. Consequently,
there is a need to identify effective interventions to optimise prescribing and resident outcomes in this context. This is an update of a
previously published review (Alldred 2013).
Objectives
The objective of the review was to determine the effect of interventions to optimise overall prescribing for older people living in care
homes.
Search methods
For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (including the Cochrane Effective
Practice and Organisation of Care (EPOC) Specialised Register), MEDLINE, EMBASE and CINAHL toMay 2015. We also searched
clinical trial registries for relevant studies.
Selection criteria
We included randomised controlled trials evaluating interventions aimed at optimising prescribing for older people (aged 65 years or
older) living in institutionalised care facilities. Studies were included if they measured one or more of the following primary outcomes:
adverse drug events; hospital admissions; mortality; or secondary outcomes, quality of life (using validated instrument); medication-
related problems; medication appropriateness (using validated instrument); medicine costs.
Data collection and analysis
Two authors independently screened titles and abstracts, assessed studies for eligibility, assessed risk of bias and extracted data. We
presented a narrative summary of results.
1Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
The 12 included studies involved 10,953 residents in 355 (range 1 to 85) care homes in ten countries. Nine studies were cluster-
randomised controlled trials and three studies were patient-randomised controlled trials. The interventions evaluated were diverse and
often multifaceted. Medication review was a component of ten studies. Four studies involved multidisciplinary case-conferencing, five
studies involved an educational element for health and care professionals and one study evaluated the use of clinical decision support
technology. We did not combine the results in a meta-analysis due to heterogeneity across studies. Interventions to optimise prescribing
may lead to fewer days in hospital (one study out of eight; low certainty evidence), a slower decline in health-related quality of life
(one study out of two; low certainty evidence), the identification and resolution of medication-related problems (seven studies; low
certainty evidence), and may lead to improved medication appropriateness (five studies out of five studies; low certainty evidence). We
are uncertain whether the intervention improves/reduces medicine costs (five studies; very low certainty evidence) and it may make
little or no difference on adverse drug events (two studies; low certainty evidence) or mortality (six studies; low certainty evidence).
The risk of bias across studies was heterogeneous.
Authors’ conclusions
We could not draw robust conclusions from the evidence due to variability in design, interventions, outcomes and results. The
interventions implemented in the studies in this review led to the identification and resolution of medication-related problems and
improvements in medication appropriateness, however evidence of a consistent effect on resident-related outcomes was not found.
There is a need for high-quality cluster-randomised controlled trials testing clinical decision support systems and multidisciplinary
interventions that measure well-defined, important resident-related outcomes.
P L A I N L A N G U A G E S U M M A R Y
Interventions to optimise prescribing for older people in care homes
Background
Older people living in care homes (also called nursing homes, residential homes, skilled-nursing facilities, assisted-living facilities or
aged-care facilities) have many complex physical and mental health problems. Care home residents are prescribed many medicines
compared to people who live in their own homes, with an average of eight medicines being common. International research has shown
that these medicines are often not well managed, with some residents prescribed medicines inappropriately. This has the potential to
lead to harmful side effects and a loss of benefit. For these reasons, it is important to make sure that care home residents are prescribed
the right medicines at the right doses. This is an update of a previously published review (Alldred 2013).
Study characteristics
We found 12 studies involving 10,953 residents in 355 care homes in ten countries that evaluated interventions to optimise prescribing
for care home residents. Most of the interventions had several components, often involving a review of medicines with a pharmacist
and doctor. Some interventions included a teaching component and one study used Information Technology (IT).
Key results
We found no evidence of benefit of the interventions with respect to reducing adverse drug events (harmful effects caused by medicines)
or death. One study led to residents having fewer days in hospital; however, the majority of studies did not show a benefit in relation
to reducing hospital admissions. One study led to a slower decline in health-related quality of life. Problems relating to medicines
were found and addressed through the interventions used in the studies. Prescribing was improved based on criteria used to assess the
appropriateness of prescribing in five studies.
Certainty of the evidence
We judged the overall quality of the evidence for the reported outcomes to be low for adverse drug events (harmful effects caused by
medicines), hospital admissions, death, quality-of-life, medication-related problems, medication appropriateness, and very low for the
cost of medicines. More high-quality studies need to be done to gather more evidence for these and other types of interventions. Further
studies are needed to evaluate new technologies, including computer systems that support prescribing decisions. More work needs to
be done to make sure that researchers are consistently measuring outcomes that are important to care home residents.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventions to optimise prescribing compared with usual GP care for care home residents
Patient or population: older people (aged 65 years or older) living in care homes
Settings: Institutionalised care facilities in Australia, Finland, Israel, Netherlands, New Zealand, Spain, Sweden, United Kingdom,
and USA and Canada
Intervention: Intervention to optimise prescribing (single or multicomponent intervention)
Comparison: Usual care by general practitioner
Outcomes Impact No of Participants
(studies)
Quality of the evidence
(GRADE)
Adverse drug events There was no evidence of an
effect on adverse drug events
1228 in 87 care homes (2 stud-
ies)
⊕⊕©©
low
Hospital admissions It is uncertain whether medica-
tion review reduces hospital ad-
missions
7606 in 309 care homes (8 stud-
ies)
⊕⊕©©
low
Mortality There was no evidence of an
effect on mortality
6805 in 188 care homes (6 stud-
ies)
⊕⊕©©
low
Quality of life It is uncertain whether medica-
tion review improves quality of
life
586 in 21 care homes (2 studies) ⊕⊕©©
low
Medication-related problems Medication review may lead to
the identification and resolution
of medication-related problems
6640 in 251 care homes (7 stud-
ies)
⊕⊕©©
low
Medication appropriateness Medication review may lead to
an improvement in medication
appropriateness
1566 in 152 care homes (5 stud-
ies)
⊕⊕©©
low
Medicine costs It is uncertain whether medica-
tion review decreases medica-
tion costs
4734 in 142 care homes (5 stud-
ies)
⊕©©©
very low
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Quality assessment of evidence for each outcome was based on study design, risk of bias, inconsistency, indirectness and imprecision.
The evidence was downgraded from high to low for adverse drug events (Crotty 2004b; Gurwitz 2008) due to a serious risk of bias
and imprecision. The evidence was downgraded from high to low for hospital admissions (Furniss 2000; Roberts 2001; Crotty 2004b;
Zermansky 2006; Frankenthal 2014; Garcia-Gollarte 2014; Pitkala 2014; Connolly 2015), mortality (Furniss 2000; Roberts 2001;
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Zermansky 2006; Frankenthal 2014; Pitkala 2014; Connolly 2015), quality of life (Frankenthal 2014; Pitkala 2014) and medication
appropriateness (Crotty 2004a; Crotty 2004b; Frankenthal 2014; Garcia-Gollarte 2014; Pitkala 2014) due to a serious risk of bias and
inconsistency. The evidence for medicines costs (Furniss 2000; Roberts 2001; Crotty 2004a; Zermansky 2006; Frankenthal 2014
was downgraded from high to very low due to a serious risk of bias, inconsistency and imprecision. The evidence for medicine-
related problems (Strikwerda 1994; Claesson 1998; Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006; Frankenthal 2014
was reduced from high to low due to design, risk of bias and imprecision.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Globally, the proportion of older people in the population is in-
creasing. The proportion of people aged 60 years and over was
11% in 2009 and this is projected to double by the middle of this
century (United Nations 2009), with developed countries experi-
encing the fastest rise in number of older people. In the United
Kingdom (UK), it is estimated that by 2034 nearly a quarter of
the population will be aged 65 years and over. The most rapid rise
has been in the ’oldest old’ that is those aged 85 years and over;
it is projected that by 2034 there will be a 2.5 fold increase in
the number of the oldest old, representing 5% of the population
(Office for National Statistics 2010). As a consequence, there will
continue to be an increasing demand for long-term care across the
world.
Long-term care may be provided in people’s homes or in insti-
tutional facilities such as nursing homes or hospitals. The termi-
nology used to describe homes that provide care for older people
(defined as 65 years or older (Department of Health 2001)) differs
across the world. In the UK the homes are known as ’care homes’,
in theUnited States (US) ’long-term care facilities’ and in Australia
’aged-care facilities’. Care homes are usually classified into two
main categories, those that provide 24-hour nursing care (nursing
homes in the UK, skilled-nursing facilities in the US and aged-
care facilities providing high-level care in Australia); and those that
provide personal care (residential homes in the UK, assisted-liv-
ing in the US and aged-care facilities providing low-level care in
Australia). Some care homes provide both types of care.
Older people living in care homes are often frail, and they are
one of the most vulnerable groups in society. They have com-
plex health needs due to multiple co-morbidities and age-related
changes in pharmacokinetics and pharmacodynamics (Armour
2002). Polypharmacy, usually defined as greater than four or more
medicines (Department of Health 2001; Rollason 2003; Patterson
2014), is common in this setting across the world with residents
prescribed an increasing number of medicines over the last decade
or so. In the UK, the mean number of medicines prescribed per
resident was 4.9 in 1998 (Furniss 2000), 6.9 in 2003 (Zermansky
2006), and by 2007 this had risen to 8.0 (Barber 2009). Many
care home residents also have cognitive impairment and this can
impede their ability to communicate medicine-related problems
(Matthews 2002; Alldred 2007a).
The complexity of prescribing for this population is compounded
by multiple clinicians prescribing. This may involve family physi-
cians and community-based consultants (for example old age psy-
chiatrists and geriatricians) in primary care; and secondary care
doctors frommultiple specialities. In addition, the lack of represen-
tation of older people in clinical trials limits the evidence base and
further increases the complexity (Beglinger 2008). It is, therefore,
perhaps unsurprising that there is extensive evidence that prescrib-
ing is suboptimal for care home residents. Inappropriate prescrib-
ing, measured using validated, explicit and implicit definitions,
has been found to be common in nursing and residential homes
in several countries including the US (Beers 1992; Hanlon 1996;
Sloane 2002; Gray 2003; Lau 2005; Perri 2005), Canada (Brymer
2003), the UK (Oborne 2003) and Australia (Crotty 2004a).
Perri 2005 found that over a one month duration, 47% of 1117
residents of 15 US nursing homes received at least one inappro-
priate medicine, with 13% of residents having at least one adverse
health outcome. Inappropriate prescribing more than doubled the
risk of a resident experiencing at least one adverse health outcome
(odds ratio (OR) 2.34, 95%confidence interval (CI) 1.61 to 3.40).
Lau 2005 reported that 50% of 3372 US nursing home residents
were prescribed at least one inappropriate medicine over one year.
The risks of hospitalisation and death were greater in those resi-
dents exposed to an inappropriate medicine (OR 1.27, 95% CI
1.09 to 1.47; OR 1.28, 95% CI 1.05 to 1.55, respectively). Gray
2003 found that 22% of 282 US residents of residential care facil-
ities were prescribed at least one inappropriate medicine. There is
also evidence that care home residents are under-prescribed ben-
eficial drugs and are poorly monitored with respect to their long-
term conditions and their medicines (Fahey 2003; Alldred 2007b;
Barber 2009).
For the reasons discussed above, care home residents are particu-
larly susceptible to adverse drug events. In two US long-term care
facilities, Gurwitz 2005 found 9.8 adverse drug events per 100
resident-months, with 42% being judged as preventable. Drug-
related problems have been found to be responsible for 3% to 31%
of hospital admissions of older people, and up to half of these are
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potentially avoidable (Howard 2007).
This is an update of a previously published review (Alldred 2013).
Description of the condition
As described above, suboptimal prescribing for older people liv-
ing in care homes is common and may occur due to the pre-
scribing of inappropriate medicines, the omission of beneficial
medicines or the failure to appropriately monitor residents and the
effects of their medicines. There are a variety of instruments that
can be employed to measure the appropriateness of prescribing in
older people (Spinewine 2007). However, the predictive validity of
these instruments on health outcomes such as adverse drug events
and hospital admissions has not been unequivocally established
(Spinewine 2007).
Description of the intervention
For this review, wewere interested in interventions concerned with
optimising the whole medication regime for care home residents,
not those concentrating solely on isolated drugs or classes such as
benzodiazepines or antipsychotics nor those concentrating on one
disease state. Financial and regulatory interventions tend to fall
into this latter category.
There are several types of interventions that can potentially opti-
mise prescribing in this setting, including:
• professional interventions, for example educational
programmes aimed at prescribers
• organisational interventions, for example medication review
services or specialist clinics, case conferencing, information and
communication technology (ICT) interventions such as clinical
decision support systems.
Medication review interventions may be aimed at specific drugs or
the whole regime and can be uni- or multiprofessional, involving
physicians, nurses and pharmacists.
How the intervention might work
Interventions designed to improve prescribing for care home res-
idents may have an impact by discontinuing inappropriate med-
ication; commencing beneficial medicines; and ensuring appro-
priate monitoring of long-term conditions and medicines. Con-
sequently, this may lead to a reduction in adverse drug events,
improved quality of life and a reduction in medicine costs.
Why it is important to do this review
There is a substantial body of evidence that prescribing for care
home residents is suboptimal and requires improvement. Fur-
thermore, there are other Cochrane reviews being undertaken
which address similar issues in different populations (Soe 2009;
Christensen 2011). We evaluated the evidence for interventions
to address suboptimal prescribing in this setting to identify how
care can be improved for this frail and vulnerable population. We
intended to achieve this by determining which interventions were
effective and by identifying gaps in the evidence to inform future
research.
O B J E C T I V E S
The objective of the review was to determine the effect of inter-
ventions to optimise overall prescribing for older people living in
care homes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included patient-randomised controlled trials (patient-RCT)
and cluster-randomised controlled trials (cluster-RCT).
Types of participants
We included studies of older people (aged 65 years or older) living
in institutionalised care facilities. Institutionalised care facilities
include: nursing homes and residential homes (UK); skilled-nurs-
ing facilities and assisted-living facilities (US); and aged-care fa-
cilities providing low-level and high-level care (Australia). If there
was any ambiguity in the description of the institution, we clari-
fied this with the authors of relevant papers. We considered trials
for inclusion if they had a majority (80% or more) of participants
aged 65 years or more, or if themean age was greater than 65 years.
We excluded studies where the intervention focused on a single
medical condition or a specific drug or class of drugs. We also ex-
cluded studies where the main focus was to reduce medication er-
rors because such studies have a narrow focus and do not consider
the whole medication regime. In addition, they do not seek to
optimise prescribing, for example by adhering to evidence-based
guidelines or by reducing inappropriate prescribing, but are de-
signed solely to reduce errors.
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Types of interventions
We assessed interventions aimed at optimising prescribing for care
home residents compared with usual care as defined by the study.
These interventions potentially included: educational interven-
tions aimed at prescribers; medication review services (uni- ormul-
tiprofessional, conducted by nurses, pharmacists or physicians);
case conferencing; and ICT interventions such as clinical decision
support systems. We excluded financial and regulatory interven-
tions.
Types of outcome measures
We included a range of outcome measures including patient-re-
lated outcomes, health service utilisation, and economic outcomes.
Studies were included if they reported at least one primary out-
come measure or at least one secondary outcome measure.
Primary outcomes
The primary outcome measures for the review were:
• adverse drug events;
• hospital admissions;
• mortality.
Secondary outcomes
Secondary outcome measures were:
• quality of life (using validated instrument);
• medication-related problems;
• medication appropriateness (using validated instrument);
• medicine costs.
Search methods for identification of studies
Paul Miller, Trials Search Co-ordinator (TSC) for Cochrane Ef-
fective Practice and Organisation of Care (EPOC) updated the
search terms used previously and conducted searches of the follow-
ing electronic databases on 14 May 2015. Searches were limited
by date to material published between 2012 and the search date.
Electronic searches
• Cochrane Central Register of Controlled Trials
(CENTRAL) 2015, Issue 4, part of The Cochrane Library.
www.cochranelibrary.com, (including Cochrane Effective
Practice and Organisation of Care (EPOC) Specialised Register)
• MEDLINE In-Process and Other Non-Indexed Citations
and Ovid MEDLINE 1946 to present, OvidSP
• EMBASE 1996 to 2015 Week 19, OvidSP
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature), 1981 to present, EbscoHost
Search strategies were comprised of keywords and, when available,
controlled vocabulary such as MeSH (Medical Subject Headings).
We applied no language restrictions. See Appendix 1 for strategies
used in this update.
Searching other resources
We searched the following trial registries for relevant studies on
18 May 2015:
• International Clinical Trials Registry Platform (ICTRP),
World Health Organization (WHO) http://www.who.int/ictrp/
en/
• ClinicalTrials.gov, US National Institutes of Health (NIH)
http://clinicaltrials.gov/
For search terms used in this update and number of results, see
Appendix 2
We also contacted authors of relevant studies to clarify reported
published information.
Data collection and analysis
Selection of studies
Two review authors (DPA and MCK) independently screened ti-
tles and abstracts to decide which studies met the inclusion crite-
ria. Any papers not meeting the inclusion criteria were excluded at
this stage. If there was uncertainty or disagreement, consensus was
reached by discussion with co-review authors. Two review authors
(DPA and MCK) independently assessed the full text articles to
ensure they still met the inclusion criteria. Full text articles not
published in English were translated prior to being assessed for
inclusion.
Data extraction and management
Two review authors (DPA andMCK) independently extracted de-
tails of articles included in the review, including the study design,
the study population, the intervention, usual care, outcome mea-
sures used and length of follow-up data, using a specially designed
data extraction form based on the EPOC template (EPOC 2013).
Where necessary, we contacted authors for missing information
or clarification. We intended to use information from the data
extraction forms to guide extraction of numerical data for meta-
analysis in Review Manager (RevMan) 5.3 (RevMan 2014).
Assessment of risk of bias in included studies
Two review authors (DPA and MCK) assessed the internal va-
lidity of each included study. We used the Cochrane Collabora-
tion’s tool for assessing risk of bias (Higgins 2011) based on six
standard criteria: adequate sequence generation; concealment of
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allocation; blinded or objective assessment of primary outcome(s);
adequately addressed incomplete outcome data; freedom from se-
lective reporting; freedom from other risk of bias. We used four
additional criteria specified by EPOC (EPOC2015): similar base-
line outcome measurements; similar baseline characteristics; reli-
able primary outcome measures; and adequate protection against
contamination. Wemade judgements as to whether studies were at
low risk, high risk or unclear risk of bias and reported all included
studies in the Cochrane ‘Risk of bias’ tables.
Measures of treatment effect
We initially planned to conduct a meta-analysis, however, this
was not possible due to heterogeneity (see Results). Therefore, we
presented a narrative summary of the results. Wherever possible,
we presented results with 95% confidence intervals.
Unit of analysis issues
We critically examined the methods of analysis of all study types.
We identified cluster-RCTs with unit of analysis errors (for exam-
ple, randomisationby care homewith analysis by residents without
adjustments for clustering) and where appropriate, commented
on unit of analysis errors in the results and discussion.
Dealing with missing data
We intended to exclude studies from a meta-analysis if there was
differential loss to follow-up between groups, greater than 20%.
However, as meta-analysis was not appropriate, this did not apply.
Assessment of heterogeneity
See Data synthesis section.
Assessment of reporting biases
We intended to examine funnel plots corresponding tometa-anal-
ysis of the primary outcome in order to assess the potential for
small study effects such as publication bias. However, this was not
possible as meta-analysis was not undertaken.
Data synthesis
We intended to synthesise the results of the studies depending on
their quality, design andheterogeneity, andwe intended topool the
results of studies if at least two studieswere homogeneous regarding
the participants, interventions and outcomes. As stated above, this
was not possible and, therefore, we presented a narrative summary.
We described studies according to setting, type of intervention
and study design together with an assessment of the evidence on
the theoretical basis for each of the approaches described.
Certainty of the evidence
We assessed the certainty of the evidence for the main compari-
son using the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) criteria (GRADE 2012) and
presented our judgements in a ’Summary of findings’ table. We
downgraded the quality of the evidence when there were concerns
about the design, risk of bias, inconsistency, indirectness and/or
imprecision. One author (DPA) made the judgements informed
by the previous version of the review (Alldred 2013) and this was
agreed by a second author (MCK).
Subgroup analysis and investigation of heterogeneity
We intended to conduct subgroup analyses for professional and
organisational interventions where possible. If we had found that
one type of intervention was common, for example medication
review, we intended to analyse this separately. If possible, we also
planned to undertake subgroup meta-analyses based on the spe-
cific nature of the intervention, for example pharmacist-led med-
ication review. However, subgroup analyses were not possible due
to heterogeneity.
See Data synthesis section for the investigation of heterogeneity.
Sensitivity analysis
We intended toperform sensitivity analysis for pooled results based
on the risk of bias. However, as we could not pool results this did
not apply.
R E S U L T S
Description of studies
We included 12 studies evaluating the effectiveness of interven-
tions to optimise overall prescribing for older people living in care
homes. See: Characteristics of included studies.
Results of the search
The searches identified 1469 articles for potential inclusion. Fol-
lowing independent screening of titles and abstracts by DPA and
MCK, nine full-text articles were assessed for eligibility and four
new studies (Frankenthal 2014; Garcia-Gollarte 2014; Pitkala
2014; Connolly 2015) met the inclusion criteria . Three stud-
ies are ongoing (Desborough ongoing; NCT02238652; Wouters
ongoing) and two were excluded (Lapane 2011; Milos 2013). See
PRISMA flowchart Figure 1 for details (Liberati 2009). The search
yielded five related systematic reviews (Kaur 2009; Ostini 2009;
Verrue 2009; LaMantia 2010; Loganathan 2011) and one nar-
rative review (Markum 2010) and their references were reviewed
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along with the references from the included studies; we did not
identify any further studies from these.
Figure 1. Study flow diagram.
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Included studies
The 12 included studies involved 10,953 residents in 355 (range
1 to 85) care homes. Three studies were conducted in Australia
(Roberts 2001; Crotty 2004a; Crotty 2004b), two in the UK (
Furniss 2000; Zermansky 2006), one in Sweden (Claesson 1998),
one in the Netherlands (Strikwerda 1994), one in the USA and
Canada (Gurwitz 2008), one in New Zealand (Connolly 2015),
one in Israel (Frankenthal 2014), one in Spain (Garcia-Gollarte
2014) and one in Finland (Pitkala 2014).
Design
Nine studies were cluster-RCTs (Strikwerda 1994; Claesson 1998;
Furniss 2000;Roberts 2001;Crotty 2004a;Gurwitz 2008;Garcia-
Gollarte 2014; Pitkala 2014; Connolly 2015) and three studies
were patient-RCTs (Crotty 2004b; Zermansky 2006; Frankenthal
2014). Two cluster-RCTs appeared to have made unit of analysis
errors in that they did not account for the effect of clustering
(Garcia-Gollarte 2014; Pitkala 2014) and therefore, P values and
95% CIs from these two studies may be over precise.There was a
wide range of study duration and follow-up between the studies,
ranging from six weeks to two years (see Table 1).
Participants
All studies involved older people living in care homes (long-term
care facilities). Mean age ranged from 81.2 years (Furniss 2000)
to 87.2 years (Gurwitz 2008) and the majority of residents were
female (range 59.7% (Crotty 2004a) to 77% (Zermansky 2006)).
The study by Roberts 2001 did not report mean age or gender.
Strikwerda 1994 studied 196 residents in one nursing home,
Claesson 1998 studied 1854 residents in 33 nursing homes, Crotty
2004a studied 154 residents in 10 high-level residential facilities,
Crotty 2004b studied 110 residents in 85 long-term care facilities,
Furniss 2000 studied 330 residents in 14 nursing homes, Gurwitz
2008 studied 1118 residents in 29 units in two long-term care fa-
cilities, Roberts 2001 studied 3230 residents in 52 nursing homes,
Zermansky 2006 studied 661 residents in 65 nursing and residen-
tial homes for older people, Frankenthal 2014 studied 359 resi-
dents in one chronic care geriatric facility, Garcia-Gollarte 2014
studied 716 residents in 36 nursing homes, Pitkala 2014 studied
227 residents in 20 assisted living facilities and Connolly 2015
studied 1998 residents in 36 residential aged care facilities.
Interventions
The interventions evaluated were diverse and often multifaceted.
Medication review (conducted by various methods) was a com-
ponent of ten studies (Strikwerda 1994; Claesson 1998; Furniss
2000; Roberts 2001; Crotty 2004a; Crotty 2004b; Zermansky
2006; Frankenthal 2014; Garcia-Gollarte 2014; Connolly
2015). Four studies involved multidisciplinary case-conferencing
(Claesson 1998; Crotty 2004a; Crotty 2004b; Connolly 2015)
and five studies involved an educational element for care home
staff (Roberts 2001; Crotty 2004a; Garcia-Gollarte 2014; Pitkala
2014; Connolly 2015). One study evaluated the use of clinical
decision support technology (Gurwitz 2008). Other components
of interventions included introducing a new professional role to
stakeholders (Roberts 2001) and the transfer of medicines infor-
mation (Crotty 2004b). Further descriptions of interventions are
presented below.
Strikwerda 1994 evaluated the effect of community pharmacist
feedback to GPs on their patients’ prescriptions over a four-week
period.
Claesson 1998 evaluated the effectiveness of monthly multidis-
ciplinary team meetings between the physician, pharmacist and
nurse(s) over 12 months. The aim of the meetings was to discuss
and improve the use of drugs. Pharmacists received a total of 65.5
hours of education and training prior to and during the interven-
tion period.
Furniss 2000 investigated the effectiveness of pharmacist-con-
ducted medication review (in addition to usual care by the GP)
versus usual care by the GP. The intervention was a single med-
ication review conducted by one pharmacist with access to med-
ical and nursing home records. No details were provided on the
education and training of the pharmacist.
The intervention evaluated by Roberts 2001 had three compo-
nents: (i) introducing a new professional role and relationship-
building; (ii) nurse education; (iii) medication review by pharma-
cists holding a postgraduate diploma in clinical pharmacy. Med-
ication reviews were undertaken for a non-random subsample of
500 residents (total intervention residents 905) selected by nurs-
ing staff. Most of the contact between pharmacists and GPs was
indirect.
Crotty 2004a evaluated the effectiveness of an ’outreach medica-
tion advisory service’. This involved a medication review prepared
by the pharmacist, followed by two multidisciplinary case confer-
ences held six to 12 weeks apart (with the GP, geriatrician, phar-
macist, care staff and an Alzheimer’s Association of South Australia
representative). No details were provided on the education and
training of the pharmacist.
Crotty 2004b investigated the effectiveness of a pharmacist tran-
sition co-ordinator for residents who were being discharged from
hospital to a long-term care facility. The intervention focused on
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the transfer of medicines information to the nursing home staff,
GP and the community pharmacist. Following this, a medication
review was conducted by the community pharmacist contracted
to the care home. In addition, the transition pharmacist co-or-
dinated a multidisciplinary case conference 14 to 28 days after
transfer involving him or herself, the GP, community pharmacist
and a nurse.
Zermansky 2006 evaluated the effectiveness of a clinical medica-
tion review (in addition to usual care by the GP) undertaken by
a pharmacist who held a post-graduate clinical pharmacy qualifi-
cation versus usual care by the GP. The pharmacist reviewed the
medicines with the medical and care home records in conjunction
with a consultation with the resident (if possible) and a nurse or
carer.
The intervention investigated by Gurwitz 2008 was a clinical de-
cision support system in facilities that had computerised provider
order entry systems. The clinical decision support system was de-
signed based on previous research on preventable adverse drug
events, criteria for suboptimal prescribing in older people and
drug-drug interactions. Warning messages were displayed to pre-
scribers in a pop-up box in real time when medicines were entered
into the computer provider order entry system. Prescribers were
free to either act on alerts or ignore them.
Frankenthal 2014 investigated pharmacist-led medication review
using the Screening Tool of Older Persons’ potentially inappro-
priate Prescriptions (STOPP) and Screening Tool to Alert doctors
to Right Treatment (START) criteria (Gallagher 2008) to identify
potentially inappropriate prescriptions and potential prescription
omissions. The chief physician decided whether to accept these
recommendations and implemented changes.
Garcia-Gollarte 2014 evaluated a structured educational interven-
tion for nursing home physicians. This involved education deliv-
ered by an expert nursing home physician on drug use in older
patients, medication review and adverse drug reactions. In addi-
tion, on-demand prescribing advice was provided to physicians
and educational material provided to participants.
Pitkala 2014 investigated educational information for nurses to
recognise harmful medicines and adverse drug events. The nurses
were then asked to identifymedication-related problems and high-
light these to the physician. In addition, two-thirds of the physi-
cians received the training.
Connolly 2015 evaluated a multifaceted complex intervention in-
volving: baseline facility assessment and care planning; monitor-
ing and benchmarking of quality-of-care indicators; multidisci-
plinary team meetings including medication review (only 23% of
the intervention group received medication review) by geriatri-
cian, nurse specialist, GP, pharmacist and nurse manager; educa-
tion and clinical coaching for nursing staff and caregivers.
Outcomes
Outcomes were diverse with differing definitions, methods of data
collection, varying time points and different reporting methods.
Studies reportedmeasures other than those specified for this review
and these are listed in theCharacteristics of included studies tables.
Primary outcome measures
Adverse drug events
Only two studies specified adverse drug events as an outcome
measure (Crotty 2004b; Gurwitz 2008). However, Crotty 2004b
did not define adverse drug events. Adverse drug events were the
primary outcome measure in the Gurwitz 2008 study and were
defined as ’an injury resulting from the use of a drug’; such adverse
drug events may have resulted from medication errors or from
adverse drug reactions in which there was no error.
Hospital admissions
Eight studies included hospital admissions as an outcome measure
(Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006;
Frankenthal 2014; Garcia-Gollarte 2014; Pitkala 2014; Connolly
2015). Furniss 2000 reported hospital admissions as the number of
inpatient days. Roberts 2001 reported the proportion of residents
hospitalised and Zermansky 2006 reported the mean number of
non-elective hospitalisations per resident. Crotty 2004b grouped
together emergency department visits and hospital readmissions.
Frankenthal 2014 reported hospital admissions (not defined).
Garcia-Gollarte 2014 reported the total number of days spent in
hospital. Pitkala 2014 reported hospital days/per person/per year.
Connolly 2015 reported ambulatory sensitive hospitalisations and
all acute admissions.
Mortality
Six studies included mortality as an outcome measure (Furniss
2000; Roberts 2001; Zermansky 2006; Frankenthal 2014; Pitkala
2014; Connolly 2015). Furniss 2000 and Zermansky 2006 re-
ported mortality as the number of deaths over eight and six
months, respectively. Roberts 2001 reported the proportion of res-
idents who had died over 12 months together with cumulative
survival. Frankenthal 2014 reported the number of deaths over 12
months. Pitkala 2014 calculated hazard ratios (HR) using the Cox
proportional hazard model. Connolly 2015 calculated the relative
risk (RR) of death over the 14 month follow up period.
Secondary outcome measures
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Quality of life
Two studies measured quality of life (Frankenthal 2014; Pitkala
2014). Pitkala 2014 used the 15dimensional instrument of health-
related quality of life (15D) and Frankenthal 2014 used the Med-
ical Outcomes Study 12-item Short-form Health survey (SF-12).
Medication-related problems
Medication-related problems from the intervention arms were
measured and classified in diverse ways in seven studies. Strikwerda
1994 reported the number of pharmacists’ recommendations and
described their type. Claesson 1998 described the type and fre-
quency of drug-related problems along with pharmacists’ recom-
mendations. Furniss 2000 measured the number of pharmacist’s
recommendations, accepted recommendations by the GP, and
the number of treatment changes. Reasons were provided for the
pharmacist’s recommendations. Roberts 2001 measured the num-
ber of medicine changes likely to be due to medication review.
Crotty 2004b identified medication-related problems and classi-
fied them into categories. Zermansky 2006 measured the num-
ber of changes in medication per participant as the primary out-
come; pharmacist’s recommendationswere identified, collated and
classified along with GPs’ acceptance of the recommendations.
Frankenthal 2014 reported the number of recommendations based
on the STOPP-START criteria along with the proportion of rec-
ommendations accepted by the physician.
Medication appropriateness
Five studies assessed medication appropriateness using a validated
tool (Crotty 2004a; Crotty 2004b; Frankenthal 2014; Garcia-
Gollarte 2014; Pitkala 2014). Crotty 2004a and Crotty 2004b
used the Medication Appropriateness Index (MAI) (Hanlon
1992). Frankenthal 2014 and Garcia-Gollarte 2014 used STOPP-
START (Gallagher 2008). Pitkala 2014 used a composite of Beers
criteria, Anticholinergic Risk Scale, > 2 psychotropic medica-
tions, nonsteroidal anti-inflammatory drugs (NSAIDs) and pro-
ton pump inhibitors.
Medicine costs
Five studies calculated medicine costs (Furniss 2000; Roberts
2001; Crotty 2004a; Zermansky 2006; Frankenthal 2014).
Furniss 2000 calculated drug costs per resident throughout the
observation and intervention phases of the study. Roberts 2001
collected yearly drug costs from prescription claims data based on
the Australian Pharmaceutical Benefits Scheme. Crotty 2004a cal-
culated monthly drug costs for all regular medicines based on the
Australian Pharmaceutical Benefits Scheme. Zermansky 2006 cal-
culated the 28-day net ingredient cost of repeat medicines per res-
ident. Frankenthal 2014 calculated medication costs per month.
Excluded studies
We excluded four studies (Avorn 1992; Crotty 2004c; Lapane
2011; Milos 2013) and we report reasons for their exclusion in
the Characteristics of excluded studies section.
Risk of bias in included studies
Studies were heterogeneous with regard to risk of bias (see Figure
2; Figure 3). Risk of bias is summarised below for each domain.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We judged nine studies to have a low risk of bias based on random
sequence generation (Furniss 2000; Roberts 2001; Crotty 2004a;
Crotty 2004b; Zermansky 2006; Gurwitz 2008; Garcia-Gollarte
2014; Pitkala 2014; Connolly 2015;). The studies by Strikwerda
1994, Claesson 1998 and Frankenthal 2014 did not report how
the sequence was generated. Seven studies utilised computer-
generated random or pseudo-random numbers (Furniss 2000;
Crotty 2004a; Crotty 2004b; Zermansky 2006; Gurwitz 2008;
Pitkala 2014; Connolly 2015;), Roberts 2001 drew from a hat
and Garcia-Gollarte 2014 used random number tables. Allocation
was adequately concealed via centralisation in two of the patient-
RCTs (Crotty 2004b; Zermansky 2006),the study by Frankenthal
2014 did not report sufficient information on allocation conceal-
ment to permit judgement. Due to the remaining nine studies
having a cluster design, we deemed them to be at low risk of bias
with regard to allocation concealment (Strikwerda 1994; Claesson
1998; Furniss 2000; Roberts 2001; Crotty 2004a; Gurwitz 2008;
Garcia-Gollarte 2014; Pitkala 2014; Connolly 2015).
Blinding
Due to the nature of the interventions it was not possible to blind
participants and personnel in any of the studies and, therefore, we
judged performance bias to be high for each study. Three stud-
ies blinded outcome assessment for subjective outcomes (Crotty
2004a; Crotty 2004b; Gurwitz 2008) and, therefore, we judged
detection bias to be low for these studies. The studies by Strikwerda
1994, Pitkala 2014 and Garcia-Gollarte 2014 did not report if
subjective outcomes were blinded and therefore, the risk was un-
clear, while the studies by Claesson 1998; Furniss 2000; Roberts
2001; Zermansky 2006; and Frankenthal 2014 we deemed to be
high risk. We deemed detection bias to be low for objective out-
comes for studies that reported them.
Incomplete outcome data
We judged five studies to be at low risk of attrition bias as they
reported similar baseline characteristics with a similar number
of dropouts for similar reasons (Crotty 2004a; Crotty 2004b;
Zermansky 2006; Frankenthal 2014; Connolly 2015). The only
outcome in theClaesson 1998 studywas a descriptionofmedicine-
related problems in the intervention group and attrition bias was
not relevant. We judged the risk of attrition bias to be unclear for
six studies due to a lack of information (Strikwerda 1994; Furniss
2000; Roberts 2001;Gurwitz 2008;Garcia-Gollarte 2014; Pitkala
2014).
Selective reporting
Although there was no evidence of selective reporting in the stud-
ies, that is, all outcome measures stated in the methods were re-
ported, research protocols were not available for all but one study
(Connolly 2015) and, therefore, we deemed that there was in-
sufficient information to permit judgement for 11 out of the 12
studies. The protocol for Connolly 2015 indicated that the pre-
specified outcomes were reported in the pre-specified way and,
therefore, we judged this to be low risk of bias.
Other potential sources of bias
Similar baseline outcome measurements
We deemed six studies (Roberts 2001; Crotty 2004b; Zermansky
2006; Frankenthal 2014; Garcia-Gollarte 2014; Connolly 2015)
to be at low risk of bias as baseline outcome measurements were
similar. We judged Furniss 2000 to be at high risk of bias be-
cause there were fewer deaths in the control group compared with
the intervention group. We also judged Crotty 2004a to be at a
high risk of bias because of baseline differences in the Medication
Appropriateness Index. We deemed the study by Pitkala 2014 to
be at unclear risk of bias because of baseline outcome measure-
ment differences in health-related quality of life and the number
of harmful medicines; however, these differences were adjusted for
in the analysis. We deemed the three remaining studies to be at
an unclear risk of bias as outcomes were not measured at baseline
(Strikwerda 1994; Claesson 1998; Gurwitz 2008).
Similar baseline characteristics
Eight studies reported similar baseline characteristics andwe there-
fore judged them to be at low risk of bias (Claesson 1998;
Roberts 2001; Crotty 2004a; Crotty 2004b; Zermansky 2006;
Frankenthal 2014; Garcia-Gollarte 2014; Connolly 2015). The
study by Strikwerda 1994 reported fewer males in group A and
fewer medicines in group B compared to group C and we judged
this to be at high risk. We deemed the study by Furniss 2000 to
be at high risk because in the control group the residents were
younger and there were fewer females. We deemed Gurwitz 2008
to be at unclear risk because baseline characteristics of residents
were not reported (although units were matched for general char-
acteristics, bed size and general characteristics of residents). We
also deemed the study by Pitkala 2014 to be at unclear risk because
there was a higher proportion of males, a higher prevalence of ’as-
needed’ medications and a higher number of co-morbidities in the
intervention group; however, these differences were adjusted for
in the analysis.
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Reliable primary outcome measure
We deemed all twelve studies to have reliable primary outcome
measures (although not all the outcome measures were included
in this review).
Adequate protection against contamination
We assessed five studies that were of a cluster design to be at
an unclear risk of adequate protection against contamination be-
cause although they were randomised by care home it was unclear
whether the healthcare professionals may have moved between
intervention and control homes (Claesson 1998; Roberts 2001;
Garcia-Gollarte 2014; Pitkala 2014; Connolly 2015).We deemed
the study by Crotty 2004a to be at low risk of contamination be-
cause in addition to the cluster design the GPs were checked to
avoid contamination between intervention and control residents.
We judged the study by Strikwerda 1994 to be at high risk be-
cause although residents were randomised by GP they all resided
in the same nursing home. Furniss 2000 randomised care homes
in different geographical areas and we therefore deemed at low risk
of contamination. Gurwitz 2008 attempted to limit the crossover
of prescribers between intervention and control units, however
some prescribers worked simultaneously on both units and conse-
quently we judged the trial to be at high risk of contamination. We
deemed the three studies that were patient-RCTs to be at high risk
as contamination was possible (Crotty 2004b; Zermansky 2006;
Frankenthal 2014).
Other bias
The medications reviews undertaken by Roberts 2001 and
Connolly 2015 were completed for a non-random subset of inter-
vention residents; we determined this to have a high risk of bias.
Garcia-Gollarte 2014 measured medication appropriateness for a
random subsample of residents, therefore the risk of bias in this
study was judged to be unclear.
Effects of interventions
See: Summary of findings for the main comparison
See Summary of findings for the main comparison for the main
comparison.
Due to the heterogeneity in interventions, outcomes and risk of
bias, it was deemed inappropriate to conduct a meta-analysis. The
effectiveness of the interventions are described below.
Primary outcome measures
Adverse drug events
Crotty 2004b found no evidence of an effect of a pharmacist
transition co-ordinator on adverse drug events (relative risk 1.05,
95% CI 0.66 to 1.68). Gurwitz 2008 tested a clinical decision
support system and found no evidence of an effect on all adverse
drug events (adjusted rate ratio 1.06, 95% CI 0.92 to 1.23) or
preventable adverse drug events (adjusted rate ratio 1.02, 95% CI
0.81 to 1.30).
Hospital admissions
Furniss 2000 found fewer inpatient days per resident in the inter-
vention group compared with the control group during the four-
month intervention phase of the study (0.55 versus 1.26); how-
ever, small numbers precluded statistical analysis. In the Roberts
2001 study, no difference was found in themean proportion of res-
idents hospitalised between the intervention and control groups.
Crotty 2004b demonstrated a reduction in the combination of
emergency room visits and hospital readmissions with a relative
risk ratio of 0.38 (95% CI 0.15 to 0.99) when analysing residents
who were alive at follow-up. When residents who had died were
included, there was no evidence of an effect on hospital admis-
sions (relative risk 0.58, 95% CI 0.28 to 1.21). Zermansky 2006
showed no evidence of an effect on the mean number of hospi-
talisations per resident (relative risk 0.75, 95% CI 0.52 to 1.07).
Frankenthal 2014 showed no evidence of an effect on the average
number of hospitalisations (intervention 0.5 ± 1.0 vs 0.5 ± 0.9
control, P = 0.10). The study by Garcia-Gollarte 2014 found a
small increase in days in hospital in the control group (+ 0.38 days,
P = 0.011) but no difference in the intervention group (+ 0.01
days, P = 0.822). Pitkala 2014 found that residents in the inter-
vention group used fewer hospital days (1.4/person/year, 95% CI
1.2 to 1.6) than control residents (2.3/person/year, 95% CI 2.1
to 2.7) (adjusted RR 0.60, 95% CI 0.49 to 0.75). It is important
to note that Garcia-Gollarte 2014 and Pitkala 2014 committed
unit of analysis errors and therefore, P-values and 95%CIs may be
over precise. Connolly 2015 showed no difference in ambulatory
sensitive hospitalisations (RR 1.07, 95% CI 0.85 to 1.36) or total
acute admissions (RR 1.02, 95% CI 0.83 to 1.26).
Mortality
Furniss 2000 found fewer deaths in the intervention group com-
pared with the control group during the intervention phase of the
study (4 versus 14, P = 0.028); however when the observation
phase of the study was taken into account, the number of deaths
in the control and intervention groups were 28 and 26 (P value
not reported), respectively. In the Roberts 2001 study, no differ-
ence was found in the mean proportion of residents who had died
between the intervention and control groups. A survival analysis
found a hazard ratio of 0.85 (95% CI 0.68 to 1.06). Zermansky
2006 showed no evidence of an effect on the number of deaths
(relative risk 1.06, 95% CI 0.70 to 1.64). Frankenthal 2014 re-
ported that 15/183 (8.2%) and 17/176 (9.7%) residents died in
the intervention and control groups respectively. However, this
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was not formally analysed as an outcome measure. Pitkala 2014
found no difference in mortality between the intervention and
control groups (adjusted HR 1.04, 95% CI 0.79 to 1.36; it should
be noted that the 95% CI may be over precise due to unit of
analysis error). Connolly 2015 showed no evidence of an effect on
mortality (RR 1.11, 95% CI 0.76 to 1.61).
Secondary outcome measures
Quality of life
Frankenthal 2014 foundnodifference between groups in the phys-
ical (P = 0.09) andmental (P = 0.70) components of SF-12. Pitkala
2014 found that health-related quality of life declinedmore slowly
in intervention residents (-0.038, 95% CI -0.054 to -0.022) than
control residents (-0.072, 95% CI -0.089 to -0.055). However,
unit of analysis error was identified for this study and therefore,
the confidence intervals may be over precise. Breathing, sleeping
and speech were the dimensions of 15D that showed differences
in favour of the intervention.
Medication-related problems
Strikwerda 1994 reported that 122 potential medication-related
problems were identified in 61 residents. As a result, nine
medicines were discontinued and four medicines had a dose re-
duction. The most common medication-related problem was a
potential interaction (51, 42%), followed by dose (31, 25%), in-
dication (23, 19%) and duration of the prescription (17, 14%).
Claesson 1998 identified 819 drug-related problems in 395 resi-
dents (2.1 per resident). The most common problem was ’choice
of drug’ (348, 43%), with the majority of these being inappro-
priate according to Swedish Medical Product Agency guidelines.
Two hundred and seventy-six (34%) problems were due to ’un-
clear indication’ whereby the team did not know why a drug had
been prescribed or the drug had not been adequately re-evaluated.
Ninety per cent (737) of the problems discussed were acted upon,
with 368 (45%) resulting in stopping themedicine and 162 (20%)
led to a change of medicine. This study evaluated 532 medicine
changes with 404 (76%) still in place after a month, 59 (11%)
discontinued and previous therapy was restored, and 69 (13%)
were difficult to evaluate as partial changes had occurred.
Furniss 2000 made 261 recommendations of which 239 (92%)
were accepted by the GP. This resulted in 144 actual treatment
changes. Thirty residents did not require a change in therapy, and
themean number of recommendations per resident (for those who
needed at least one recommendation) was 2.46 (range 0 to 7). The
most common reasons for recommendations were ’indication for
the medication no longer present’ (85, 33%) and ’safer or more
efficacious use of drug’ (77, 30%).
Roberts 2001 followed up 137 of the 500 medication reviews
conducted and found that 54 (39%) of the residents had changes
likely to be due to the review.No further informationwas provided.
Crotty 2004b identified medicine-related problems at admission
to the long-term care facility for intervention and control resi-
dents. The most common issue classified as a medicine-related
problem by the authors was that a resident had been appointed a
new physician. The next most common problems identified were:
discrepancy between medication discharge summary and medica-
tion (32, 57% intervention; 26, 48% control); precaution with
use (18, 32% intervention; 14, 26% control); no indication for
medication (18, 32% intervention; 8, 15% control).
In the study by Zermansky 2006, at least one recommendation
was made in 256 (77%, 95% CI 73.1 to 81.7) residents, with
a mean of 2.3 recommendations per resident. The study made
672 medication-related recommendations, along with an addi-
tional 75 recommendations related to the residents’ conditions.
The most common recommendation was technical (for example
generic switching, amending quantities, removing discontinued
items from the repeat prescription) with 225 (30%) recommen-
dations. Following technical reasons, the most common recom-
mendations were to conduct a test to monitor therapy (161, 22%)
and to stop a medicine (100, 13%). The GP accepted 565 (76%)
of the pharmacist’s recommendations and rejected 52 (7%); there
was no response to the review or the resident died before the review
could be actioned in the remaining cases. The GP actioned 433
(77%) of the accepted recommendations.
Frankenthal 2014 made 327 recommendations in total including
245 in 129 residents based on STOPP and 82 in 65 residents based
on START. 82.4% of STOPP recommendations and 92.6% of
START recommendations were accepted by the physician.
Medication appropriateness
Crotty 2004a found that, based on the Medication Appropriate-
ness Index (MAI), medication appropriateness improved in the
intervention group (MAI mean change 4.1, 95% CI 2.1 to 6.1)
compared with the control group (MAImean change 0.4, 95%CI
-0.4 to 1.2). MAI scores were higher at baseline for intervention
group residents compared with control residents (mean MAI 7.4,
95% CI 4.5 to 10.3 versus 4.1, 95% CI 2.4 to 5.7). There were no
baseline differences in meanMAI scores between the control (3.7,
95% CI 2.2 to 5.2) and intervention groups (3.2, 95% CI 1.8 to
4.6) in the Crotty 2004b study. Following the intervention, there
was no change in MAI in the intervention group (2.5, 95% CI
1.4 to 3.7) whereas the MAI in the control group had worsened
(6.5, 95% CI 3.9 to 9.1). The effect of the intervention on MAI
scores remained when controlled for baseline MAI, Charlson Co-
morbidity Index and the number of drugs discontinued during
hospital admission.
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Based on STOPP-START criteria at six months’ follow-up,
Frankenthal 2014 found a reduction in potentially inappropriate
prescriptions (37.4% intervention vs 56% control, P < 0.01) and
potential prescribing omissions (9.2% intervention vs 25.2% con-
trol, P < 0.01) in intervention residents at six months’ follow-up
and this was sustained at 12 months.
Garcia-Gollarte 2014 evaluated medication appropriateness using
STOPP-START criteria in a random subsample of 411 residents
(200 control, 211 intervention). At follow-up, the mean number
of inappropriate drugs was lower in the intervention group than
the control group (0.81 ± 1.13 vs 1.29 ± 1.56) with a decrease
from baseline in the intervention group (P < 0.01) and an increase
from the baseline in the control group (P < 0.01). The proportion
of participants without potentially inappropriate prescriptions in-
creased in the intervention group (33.2% at baseline vs 56.4%
at follow-up), as opposed to the control group where there was
no change (37.6% at baseline vs 38.7% at follow up). Potential
prescribing omissions decreased in the intervention group (0.91 ±
1.19 at baseline vs 0.13 ± 0.44 at follow up) whereas there was no
change in the control group. As noted for this study previously,
Garcia-Gollarte 2014 appeared to commit a unit of analysis error
and therefore, P values and confidence intervals may be over pre-
cise.
Pitkala 2014 found no change in the prevalence of harmful med-
ication use in control residents (3.4%, 95% CI -3.7 to 10.6) at
follow-up, however there was a decrease in the intervention group
(-11.7, 95% CI -20.5 to -2.9). Similarly, there was a decrease in
the mean number of harmful medicines in intervention residents
(-0.43, 95% CI -0.15 to -0.71) but no corresponding change in
control residents (0.11, 95% CI -0.09 to 0.31). It should again be
noted that unit of analysis error was identified in this study and
therefore, confidence intervals may be over precise.
Medicine costs
The cost of medicines per resident in the observation phase of
Furniss 2000 was GB Pounds (GBP) 142.53 in the control group
and GBP 159.01 in the intervention group. Following the inter-
vention phase, costs were GBP 141.24 in the control group versus
GBP 131.54 in the intervention group, representing a reduction
in medicine costs of GBP 27.47 per resident over a four-month
period. Accounting for the pharmacist’s time, the cost saving on
medicines in the intervention group was calculated to be GBP
22 per resident. Roberts 2001 calculated a drug cost saving of
Australian Dollars (AUD) 64 per resident per year in the inter-
vention group compared to the control group. When the cost of
the intervention was accounted for, the net cost saving was AUD
16 per resident per year. Crotty 2004a found no difference in
mean medicine costs per month per resident between the inter-
vention and control groups (mean change AUD 5.72 interven-
tion vs AUD 3.37 control, P = 0.837). Zermansky 2006 reported
little difference on the cost of 28 days’ repeat medicines per res-
ident (mean difference GBP -0.70, 95% CI GBP -7.28 to GBP
5.71). Frankenthal 2014 demonstrated a reduction in the average
monthly medication costs in the intervention group at follow-up
compared to baseline (382.7 ± 279.3 at baseline vs 279 ± 171.9 at
follow-up, Israeli New Shekel (ILS), P < 0.01), with a difference
between the intervention group and control group at follow up
(279 ± 171.9 vs 402.3 ± 291.2, ILS, P < 0.01).
Certainty of the evidence
The overall quality/certainty of the evidence for the outcomes
reported was judged to be low or very low, see: Summary of
findings for the main comparison. The evidence was downgraded
from high to low for adverse drug events (Crotty 2004b; Gurwitz
2008) due to a serious risk of bias and imprecision. The evi-
dence was downgraded from high to low for hospital admissions
(Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006;
Frankenthal 2014; Garcia-Gollarte 2014; Pitkala 2014; Connolly
2015), mortality (Furniss 2000; Roberts 2001; Zermansky 2006;
Frankenthal 2014; Pitkala 2014; Connolly 2015), quality of life
(Frankenthal 2014; Pitkala 2014) andmedication appropriateness
(Crotty 2004a; Crotty 2004b; Frankenthal 2014; Garcia-Gollarte
2014; Pitkala 2014) due to a serious risk of bias and inconsistency.
The evidence for medicines costs (Furniss 2000; Roberts 2001;
Crotty 2004a; Zermansky 2006; Frankenthal 2014 was down-
graded from high to very low due to a serious risk of bias, in-
consistency and imprecision. The evidence for medicine-related
problems (Strikwerda 1994;Claesson 1998; Furniss 2000;Roberts
2001; Crotty 2004b; Zermansky 2006; Frankenthal 2014 was re-
duced fromhigh to low due to design, risk of bias and imprecision.
D I S C U S S I O N
Summary of main results
12 studies were included in the review and three ongoing stud-
ies. The primary outcomes of the review were adverse drug
events, mortality and hospital admissions.There was no evidence
of an effect of the interventions on adverse drug events (Crotty
2004b;Gurwitz 2008) andmortality (Furniss 2000;Roberts 2001;
Zermansky 2006; Frankenthal 2014; Pitkala 2014; Connolly
2015). There was evidence from one study that the interven-
tion led to fewer days in hospital (Pitkala 2014); however, there
was no evidence of an effect in the remaining studies (Furniss
2000;Roberts 2001;Crotty 2004b;Zermansky 2006; Frankenthal
2014; Garcia-Gollarte 2014; Connolly 2015). One study found
evidence that the intervention led to a slower decline in health-
related quality of life (Pitkala 2014) with one study showing no
effect on quality of life (Frankenthal 2014). There was evidence
that the interventions led to the identification and resolution of
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medication-related problems (Strikwerda 1994; Claesson 1998;
Furniss 2000; Roberts 2001; Crotty 2004b; Zermansky 2006;
Frankenthal 2014). There was evidence from five studies that
medication appropriateness was improved (Crotty 2004a; Crotty
2004b; Frankenthal 2014; Garcia-Gollarte 2014; Pitkala 2014).
However, the link between improved medication appropriateness
and patient-related outcomes is not clear. The evidence for an ef-
fect on medicine costs was mixed with three studies finding a re-
duction in costs (Furniss 2000; Roberts 2001; Frankenthal 2014)
and two studies finding no difference (Crotty 2004a; Zermansky
2006).
Overall completeness and applicability of
evidence
The review was designed to identify interventions that consid-
ered residents’ whole medication regimens to optimise prescrib-
ing. Consequently, a broad range of interventions (professional
and organisational) were eligible for the review and diverse, multi-
faceted interventions were ultimately implemented to address the
objectives of the review.
The interventions were tested in the population of interest; how-
ever, there was considerable variability in the outcomes measured
with quality of life only represented in two of the included studies
(Frankenthal 2014; Pitkala 2014).
Current practice varies considerably internationally. Multidisci-
plinary teams (involving physicians, nurses and pharmacists) play
a significant role in optimising prescribing for care home residents
and this was reflected in the studies; the majority of interven-
tions involved multidisciplinary teamwork, usually with pharma-
cists conducting medication reviews. However, the effectiveness of
this has not been demonstrated. Information and communication
technology is increasingly being employed to optimise prescribing
in many settings, and one study tested the impact of a clinical
decision support system (Gurwitz 2008).
Quality of the evidence
We could not draw robust conclusions from the evidence due to
variability in design, interventions, outcomes and results. The re-
view included 12 studies of varying quality that included 10,953
residents living in 355 care homes in ten countries and are sum-
marised in the ’Summary of findings’ table (Summary of findings
for the main comparison). The overall quality of the evidence for
the outcomes reported was judged to be low or very low and there-
fore, there is uncertainty of the effect of interventions to optimise
prescribing in this context. The interventions that were tested may
reduce medication-related problems and improve medication ap-
propriateness; however, there may be little or no difference in ad-
verse drug events, mortality, quality-of-life or hospital admissions.
It is also uncertain whether the interventions decrease medica-
tion costs. The majority of the included studies were cluster-RCTs
and this was appropriate given the complex nature of interven-
tions, the difficulty of blinding and the consequential threat of
contamination. However, two of the nine cluster-RCTs appeared
to commit unit of analysis errors. The patient-RCTs did not ad-
equately protect against contamination and, therefore, the effects
of the intervention may have potentially been diluted. Some of the
studies had short follow-up periods, which may have potentially
limited the detection of effects on outcomes. None of the studies
blinded participants and personnel; although this was unlikely to
have been achievable due to the nature of the interventions, it
may still introduce bias. The interventions tested were complex
and multifaceted and none of the studies attempted to disentan-
gle the ’black box’ effect, that is to understand the effects of the
contributing components. Not all the studies attempted blinding
of assessment for subjective outcomes, and this could have been
implemented. Amajor limitation of the evidence was the diversity
of outcome measures and the fact that they differed in the way
they were defined (if at all), collected and analysed.
Potential biases in the review process
We minimised bias when conducting this review by several meth-
ods.We conducted an extensive literature searchwhich was guided
by EPOC and we screened the included studies from published
systematic reviews.We did not limit studies to those in the English
language. Two review authors independently screened titles and
abstracts, assessed studies for eligibility, evaluated risk of bias and
extracted data.
Agreements and disagreements with other
studies or reviews
We identified five previously published systematic reviews (Kaur
2009; Ostini 2009; Verrue 2009; LaMantia 2010; Loganathan
2011) and one narrative review (Markum 2010) related to the
objectives of this review. We did not identify further studies from
these reviews and the conclusions were similar, that is mixed re-
sults were obtained from the several intervention types tested in
heterogeneous studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The interventions implemented in the studies in this review led to
the identification ofmedication-related problems, confirming that
suboptimal prescribing is prevalent in this context. The majority
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of medication-related problems were resolved through the inter-
ventions employed. In addition, evidence from five studies sug-
gested that the appropriateness of medication could be improved
through multifaceted interventions involving medication review
by pharmacists, transfer of information and multidisciplinary case
conferencing. Despite the identification and resolution of medi-
cation-related problems, and improvements in medication appro-
priateness, there is a lack of evidence on how this translates to
improvements in resident-related outcomes, namely adverse drug
events, hospital admissions, mortality and quality of life. The ef-
fect of interventions on medicine costs was unclear, with three
studies showing a reduction in costs and two studies showing no
difference.
Implications for research
High-quality, adequately powered RCTs, ideally using cluster de-
signs, need to be conducted to identify effective interventions to
optimise prescribing for older care home residents. More studies
are needed to investigate the effectiveness of clinical decision sup-
port systems as well as multidisciplinary interventions in this con-
text. Further work is required to develop consensus on identifying,
defining, measuring, reporting and analysing important resident-
related outcomes, including quality of life. This will enable meta-
analyses to be conducted on future RCTs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Claesson 1998
Methods Cluster-RCT (randomised by nursing home)
Total study duration: 14 months
Participants 1854 residents
33 nursing homes
Setting: nursing homes
Age: Average 83 years
Gender: Intervention 70% female; control 67% female
Country: Sweden
Date of study: 1994/95
Interventions The aim of the regular multidisciplinary meetings was to discuss and improve the use
of drugs in nursing homes, and to decrease the use of drugs which, according to the
advice of the workshop arranged by the Swedish Medical Products Agency, could cause
confusion and impaired memory. In group discussions, the physician, pharmacist, one
or more of the nursing home nurses, and in many cases, one or more of the assistant
nurses and nurse aides reviewed the drug use of all residents on a monthly basis over
a period of one year. The length and frequency of the meetings were adjusted by the
participants to local conditions. The therapy changes that were discussed were thus based
on the physician’s medical knowledge, the pharmacist’s pharmaceutical knowledge, and
the nurses’ and other staff ’s knowledge about the patients’ social and functional status.
The selected pharmacists were educated prior to and during the intervention period. This
education took the form of lectures and workshops, which took place on five occasions,
twice before the intervention started and three times during the intervention period, for
a total of 65.5 hours. The lectures were given by recognised experts, including clinical
pharmacists, geriatricians, gerontologists, nurses and two community pharmacists with
experience in nursing home consulting. Topics covered were gerontology/geriatrics (12.
5 hours), drug use in the elderly (23.5 hours) and basic training in collaborative methods
(18.5 hours). In addition, the pharmacists worked with patient cases in small groups,
covering all the areas mentioned above (11 hours). In addition to the formal education,
the pharmacists formed regional networks. The networking took place locally, whenever
the pharmacist felt a need to have it. In order to make the networks constructive, the
whole group was instructed by an educational specialist on one occasion
Outcomes Medication-related problems
Not used for this review:
Drug use
Notes Supported by the National Corporation of Swedish Pharmacies and the Swedish Phar-
maceutical Society
Risk of bias
Bias Authors’ judgement Support for judgement
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Claesson 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk Homes were matched in pairs then each
randomised to control or intervention. [At-
tempted to contact author for further in-
formation but unsuccessful]
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No objective outcomes
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Medication-related problems described for
residents receiving intervention
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Unclear risk Medication-related problemsnotmeasured
at baseline
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Drug use
Adequate protection against contamina-
tion
Unclear risk Cluster design. [Attempted to contact au-
thor for further information but unsuccess-
ful]
Other bias Low risk Appears to be free of other sources of bias
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Connolly 2015
Methods Cluster-RCT (randomised by care facility)
Total study duration: 14 months
Participants 36 facilities (18 intervention, 18 control). 1998 residents (1123 intervention, 875 con-
trol)
Setting: Residential aged-care (RAC) facilities
Age: mean age not provided. Intervention: < 65, 6.4%; 65 to 74, 11.7%; 75 to 84, 29.
5%; 85 to 94, 46.6%; 95 + 5.9%; control < 65, 7.5%; 65 to 74, 11.2%; 75 to 84, 29.
1%; 85 to 94, 43.3%; 95 + 8.8%
Gender: Intervention male 348 (31.0%), control male 242 (27.7%)
Country: New Zealand
Date of Study: 2010-2012
Interventions 1. Baseline facility assessment to identify areas of need and facility care plan developed
in collaboration with the gerontology nurse specialist (GNS), and RAC facility clinical
leadership (anonymised example available from authors on request)
2.Monitoring and benchmarking of resident indicators linked to quality of care provided
(falls, nutrition, restraint use, weight loss, urinary tract infections, residents on nine
medications); benchmarking was provided on three occasions during the intervention
3. Three 1-hour multidisciplinary team (MDT) meetings, monthly for the first three
months at each facility, including medication review by study geriatrician, GNS, general
practitioner (GP), pharmacist, and nurse manager. Typically, six residents were
considered per meeting with priority given to new admissions, the recently hospitalised,
those with recent “incidents” (e.g., fall), and those on nine or more medications
4. Gerontology education and clinical coaching for RACnurses and caregivers, including
advanced (end-of-life) care planning, nutrition/hydration, early detection of illness, falls
prevention, end-stage dementia care, communication with families, and practical aspects
of care
Outcomes Hospital admissions (ambulatory sensitive hospitalisations, total acute admissions)
Mortality
Notes Funded by the Health Research Council of New Zealand
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomised numbers
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not conducted
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Connolly 2015 (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk No subjective outcomes measured
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Authors state that “’care was taken to
blind investigators to facility identification
wherever possible”. However outcomes not
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
Primary outcomes
Low risk Reasons for attrition reported. Described
as intention-to-treat by authors
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Reasons for attrition reported. Described
as intention-to-treat by authors
Selective reporting (reporting bias) Low risk Pre-specified outcomeswere reported in the
pre-specified way in the protocol
Similar baseline outcome measurements Low risk Similar baseline outcome measurements
(no baseline measurement of hospital ad-
missions)
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Hospital admissions
Adequate protection against contamina-
tion
Unclear risk Cluster design. However, it was theoreti-
cally possible that some healthcare profes-
sionals may have moved between interven-
tion and control nursing homes [author
contacted]
Other bias High risk Medication reviews were undertaken for
a non-random subsample of 23% of in-
tervention residents selected by multidisci-
plinary team
Crotty 2004a
Methods Cluster-RCT (randomised by care facility)
Total study duration: 3 months
Participants 10 facilities (5 intervention, 5 control). 154 residents (50 intervention, 54 control, 50
within-facility control)
Setting: High-level residential aged-care facilities (nursing homes)
Age: Intervention mean 85.3, control mean 83.6, within-facility control mean 84.6
Gender: Intervention male 22 (44%), control male 23 (43%), within-facility control
26Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Crotty 2004a (Continued)
male 17 (34%)
Country: Australia
Date of Study: 1999 [Author contacted]
Interventions Outreach geriatric medication advisory service, case conferencing and medication review
GPs were invited to attend two multidisciplinary case conferences conducted 6 to 12
weeks apart. The resident’s GP, a geriatrician, a pharmacist, residential care staff and
a representative of the Alzheimer’s Association of South Australia attended the case
conferences, which were held at the facility. Residential care staff expanded on any issues
in the case notes that required discussion and the Alzheimer’s Association of South
Australia representative discussednon-pharmacologicalmanagement of dementia-related
behaviour. Each case conference was chaired by the GP, who used their medical records
in addition to case notes from the facility. A problem list was developed by the GP in
conjunction with the care staff and a medication review was conducted prior to each
case conference. All facilities in the study, including those in the control group, received
a half-day workshop provided by the Alzheimer’s Association of South Australia, which
examined the use of a toolkit in the management of challenging behaviours
Outcomes Measured at baseline and three months post-intervention:
Medication appropriateness (MAI)
Drug costs (based on Australian Government Pharmaceutical Benefits Scheme)
Not used in this review:
Nursing Home Behaviour Problem Scale (NHBPS)
Number of drugs
Notes Funded by The Quality Use of Medicines Evaluation Programme 2000-2001, Health
and AgedCare, General Practice National Innovations Funding Pool 1999-2000, Health
and Aged Care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
used
Allocation concealment (selection bias) Low risk A researcher independent to the investiga-
tors generated the random sequence and
cluster design. Staff were asked to “nomi-
nate” 20 residents from intervention sites
and 10 residents from control sites. From
the 20 intervention,10 were randomised
to intervention and ten to within-facility
control using sequential sealed opaque en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
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Crotty 2004a (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Assessed by independent pharmacist
blinded to allocation [author contacted]
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Reasons for attrition reported (all due to
deaths) and no statistically significant dif-
ference found in the proportionof residents
lost between groups
Described as intention-to-treat analysis by
authors
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements High risk There were differences in the Medication
Appropriateness Index between groups at
baseline: Control 4.1 (95% CI 2.4-5.7);
Within-facility control 6.0 (95% CI 3.1-9.
0); Intervention 7.4 (95% CI 4.5-10.3)
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Medication Appropriateness Index
Adequate protection against contamina-
tion
Low risk Cluster design. Randomised by care facil-
ity. GPs were checked to avoid contamina-
tion between intervention and control res-
idents [author contacted]. No significant
differences found between the within-facil-
ity control and the control groups, there-
fore no evidence of a carry-over effect of the
intervention
Other bias Low risk Appears to be free of other sources of bias
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Crotty 2004b
Methods RCT (randomised by patient)
Total study duration: 8 weeks
Participants 110 patients (56 intervention, 54 control) from three hospitals discharged to 85 long-
term facilities
Setting: Long-term care facilities
Age: Mean 82.7, .SD 6.4
Gender: 67 women (60.9%), 43 men (39.1%)
Country: Australia
Date of study: October 2002 to July 2003
Interventions Pharmacist transition co-ordinator
The intervention focused on transferring information on medications to care providers
in the long-term care facilities, including the nursing staff, the family physician and the
accredited community pharmacist. On the patient’s discharge from the hospital to the
long-term care facility both the family physician and the community pharmacist were
faxed a medication transfer summary compiled by the transition pharmacist and signed
by the hospital medical officer. This communication supplemented the usual hospital
discharge summary and included specific information on changes to medications that
had been made in the hospital and aspects of medication management that required
monitoring
After transfer of the patient to the long-term care facility, the transition pharmacist
co-ordinated an evidence-based medication review that was to be performed by the
community pharmacist contracted to the facility within 10 to 14 days of the transfer.
The transition pharmacist also co-ordinated a case conference involving him or herself,
the family physician, the community pharmacist and a registered nurse at the facility
within 14 to 28 days of the transfer. At this case conference, the transition pharmacist
provided information concerning medication use and appropriateness
The usual hospital discharge process received by the control group included a standard
hospital discharge summary
Outcomes Measured at baseline and eight weeks post-discharge:
Adverse drug events (not defined)
Hospital admissions (emergency department visits and hospital readmissions)
Medication-related problems
Medication appropriateness (MAI)
Not used for this review:
Falls
Worsening mobility
Worsening behaviours
Increased confusion
Worsening pain
Notes Funded by the Australian Commonwealth Department Of Health and Ageing National
Demonstration Hospitals Program
Risk of bias
Bias Authors’ judgement Support for judgement
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Crotty 2004b (Continued)
Random sequence generation (selection
bias)
Low risk Study biostatistician provided a computer-
generated allocation sequence using block
randomisation
Allocation concealment (selection bias) Low risk Randomisation was co-ordinated by a cen-
tralised hospital pharmacy service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Independent pharmacists blinded to alloca-
tion assessed Medication Appropriateness
Index (MAI)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Similar Medication Appropriateness Index
scores at baseline. Other outcomes not
measured at baseline
Similar baseline characteristics Low risk Similar baseline characteristics reported ex-
cept more pre-admission medications dis-
continued during hospitalisation in the
control group
Reliable primary outcome measure Low risk Medication Appropriateness Index
Adequate protection against contamina-
tion
High risk Randomised by patient therefore contami-
nation possible
Other bias Low risk Appears to be free of other sources of bias
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Frankenthal 2014
Methods RCT (randomised by patient)
Total study duration: 1 year
Participants 359 residents (176 control, 183 intervention)
Setting: Chronic care geriatric facility
Age: Mean 82.7
Gender: Intervention male 29.5%, control male 37.5%
Country: Israel
Date of Study: Not Stated
Interventions The intervention consisted of a medication review by the study pharmacist for all resi-
dents at study opening and six and 12 months later. The STOPP/START criteria were
applied to identify potentially inappropriate prescriptions (PIPs) and potential prescrip-
tion omissions (PPOs). Interventional recommendations that the study pharmacist made
for residents in the intervention group but not in the control group were discussed with
the chief physician at study opening and after six months. The chief physician decided
whether to accept these recommendations and implement prescribing changes
Outcomes Measured at baseline and at 12 months:
Hospital admissions (not defined)
Mortality
Quality of life (Medical Outcomes Study 12-item Short-Form Health Survey [SF-12])
Medication-related problems (number of pharmacist recommendations,
acceptance of recommendations by the physician, number of treatment changes)
Medication appropriateness (STOPP-START)
Medication costs (Average monthly medication costs in Israeli Shekels)
Not used for this review:
Falls
Functioning (Functional Indepence Measure)
Notes Study was supported partly by a research grant from Keshet Association for the Elderly
in Tel-Aviv-Yaffo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Nurses who were unaware of group assign-
ments assessed outcome measures. How-
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Frankenthal 2014 (Continued)
ever, the study pharmacist collected data on
outcome measures at follow-up
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Nurses who were unaware of group assign-
ments assessed outcome measures. How-
ever, the study pharmacist collected data on
outcome measures at follow-up. Outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Low risk Reasons and proportions for attrition doc-
umented and similar in intervention and
control
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Reasons and proportions for attrition doc-
umented and similar in intervention and
control
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Similar baseline outcomes for falls, hospi-
talisations and medicine costs
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Falls and hospitalisations
Adequate protection against contamina-
tion
High risk Randomised by patient therefore contami-
nation possible
Other bias Low risk Appears to be free from other sources of
bias
Furniss 2000
Methods Cluster-RCT (randomised by care home)
Total study duration: 8 months
Participants 330 residents (172 control, 158 intervention); 14 homes (7 matched pairs)
Setting: Nursing homes
Age: Control mean 78.9 SD 13.7; intervention mean 83.5 SD 9.2
Gender: Control 115 (67%) females; intervention 125 (79%) females
Country: UK
Date of study: Not stated
Interventions Medication review by pharmacist
Medication review by the study pharmacist in the GP’s surgery, at the nursing home or
(in exceptional circumstances) over the telephone. The pharmacist collected details of
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Furniss 2000 (Continued)
current medication for each resident from the medicines administration record chart in
the home, together with a brief medical history and any current problems identified by
the home staff. Three weeks after the medication review, the homes were revisited, to
ascertainwhether there hadbeen any immediate problemswith the changes inmedication
and to see if the suggested changes had been implemented
Outcomes Measured at time 0 (beginning of study), time 1 at four months (beginning of interven-
tion) and at time 2 at eight months (end of intervention):
Hospital admissions (“inpatient days”)
Mortality
Medication-related problems (number of pharmacist recommendations,
acceptance of recommendations by the GP, number of treatment changes)
Medication costs (not defined, £ sterling)
Not used for this review:
Mini-Mental State Examination (MMSE)
Geriatric Depression Scale (GDS)
Brief Assessment Schedule Depression Cards (BASDEC)
Crichton-Royal Behaviour Rating Scale (CRBRS)
Number of drugs per resident
Type of drugs
Reason for neuroleptic use
Use of primary and secondary care resources
Number of accidents
Falls
Notes Funded by the North West NHS Executive
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated pseudo random
numbers used
Allocation concealment (selection bias) Low risk Homes were randomised at the start of the
start of a four-month observation phase.
Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding described
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
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Furniss 2000 (Continued)
Objective outcomes ing
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements High risk 14 (8.1%) deaths in control group versus
22 (13.9%) deaths in intervention group
at baseline. No baseline measurements of
other primary outcomes of this review
Similar baseline characteristics High risk Slightly fewer residents in the interven-
tion group (158) versus control (172). In
the control group, residents were younger
(mean 78.9 SD 13.7 versus mean 83.5 SD
9.2) and therewere fewer females (67%ver-
sus 79%)
Reliable primary outcome measure Low risk Crichton-Royal Behaviour Rating Scale
Adequate protection against contamina-
tion
Low risk Randomised by care home (which were in
different geographical areas)
Other bias Low risk Appears to be free of other sources of bias
Garcia-Gollarte 2014
Methods Cluster-RCT (randomised by nursing home)
Total study duration: 6 months
Participants Control group: 17nursinghomes and29doctors (372 participants). InterventionGroup:
19 nursing homes and 30 doctors (344 participants)
Setting: Nursing homes
Age: Control mean 84.5 SD 10.4 ; intervention 84.24 mean SD 14.6
Gender: Control 72.1% female; intervention 74.0% female
Country: Spain
Date of study: February 2010 to February 2013
Interventions Educational intervention delivered to 30 doctors
Nursing home physician expert in drug use in older people delivered a structured ed-
ucational intervention. The educational intervention included information on general
aspects of prescription and drug use in geriatric patients, how to reduce the number of
drugs and to perform regular reviews of medications, to avoid inappropriate drug use,
34Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Garcia-Gollarte 2014 (Continued)
to discontinue drugs that do not show benefit and to avoid under-treatment with drugs
that have shown benefit. Information also provided on adverse drug reactions in older
people
Educational material and references also provided to participants
Educator also provided on-demand prescription advice (via phone) for a six-month
period
Outcomes Measured at baseline and at nine months.
Hospital admissions (total number of days spent in hospital)
Medication appropriateness (STOPP-START)
Not used in this review:
Falls
Delirium
Physician and nurse visit
Emergency room visits
Use of antipsychotics
Use of delirium drugs
Notes Funded by the Ballesol group [author contacted]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Outcomes not likely to be influenced by
lack of blinding
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Per protocol analysis used. Dropouts were
not identified by group
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Per protocol analysis used. Dropouts were
not identified by group
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Garcia-Gollarte 2014 (Continued)
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Similar baseline outcome measurements
for days in hospital and medication appro-
priateness
Similar baseline characteristics Low risk Similar baseline characteristics reported ex-
cept worse functional status in intervention
group; however, adjusting for this did not
significantly change the results
Reliable primary outcome measure Low risk Objective measures of healthcare utilisa-
tion
Adequate protection against contamina-
tion
Unclear risk Cluster design. However, it was theoret-
ically possible that some physicians may
havemoved between intervention and con-
trol nursing homes [author contacted]
Other bias Unclear risk For prescribing appropriateness, a random
sample of 311 from1018 residentswas used
Gurwitz 2008
Methods Cluster-RCT (randomised by care unit within two long-term care facilities)
Total study duration: 12 months
Participants 1,118 resident in 29 units in two long-term care facilities
Setting: Long-term care facilities
Age: Average 87.2 years
Gender: 71.3% female
Country: US and Canada
Date of study: 2006-7 [Author contacted]
Interventions Computerised provider order entry with clinical decision support
A team of geriatricians, pharmacists, health services researchers and information system
specialists designed the clinical decision support system
The team reviewed the types of preventable adverse drug events based on previous
research and widely accepted published criteria for suboptimal prescribing in elderly
people available at the time of this study. All serious drug-drug interactions from a
standard pharmaceutical drug interaction database were also reviewed and alerts were
included for a limited number of more than 600 potentially serious interactions that
were reviewed. For residents on the intervention units, the alerts were displayed in a pop-
up box to prescribers in real time when a drug order was entered. The pop-up boxes
were informational; they did not require specific actions from the prescriber and did not
produce or revise orders automatically. On the control units, the alerts were not displayed
to the prescribers
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Outcomes Measured throughout study period (resident-months):
Adverse drug event (“an injury resulting from the use of a drug” includes medication
error and adverse drug reaction)
Severity of adverse drug event
Preventability of adverse drug event
Notes Supported by the Agency for Healthcare Research and Quality.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation used. Within each
block, units were randomly assigned using
the random function in Microsoft Excel®.
[Author contacted]
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Outcome assessors were blind to allocation
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk No objective outcomes
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Not measured in this study
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Unclear risk No baseline measurements of adverse drug
effects
Similar baseline characteristics Unclear risk Baseline characteristics not reported, how-
ever, units were matched for bed size and
general characteristics of residents and the
unit
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Reliable primary outcome measure Low risk Number of adverse drug events
Adequate protection against contamina-
tion
High risk Cluster design. Efforts were made to limit
crossover of prescribers between interven-
tion and control units, however, some pre-
scribers worked simultaneously on both in-
tervention and control units. In an effort
to assess the possibility that this may have
led to changes in behaviour in the con-
trol group, the rate of responses to “unseen”
alerts in the control units during the first
versus the last quarter of the study was as-
sessed at one of the study sites. The rate of
response was lower in the last quarter, sug-
gesting that prescribers did not adopt new
habits due to seeing alerts on intervention
units
Other bias Low risk Appears to be free of other sources of bias
Pitkala 2014
Methods Cluster-RCT (randomised by ward)
Total duration of study: 12 months
Participants 227 residents in 20 facilities (10 control, 10 intervention)
Setting: Assisted living facilities
Age: Control mean 83.5 SD 6.9; intervention mean 82.9 years SD 7.5
Gender: Control 77.1% female; intervention 65.3% female
Country: Finland
Date of Study: Not stated
Interventions Educational intervention:
Two 4-hour training sessions for nursing staff. Aim of session was to enable nurses to
recognise harmful medications and corresponding adverse drug events
First 4-hour session: lecture-based, allowed participants to discuss medication-related
problems experienced by their own residents, introduced lists of harmful medications
and suitable treatments. Also involved discussion about medication use for residents with
real impairment and drug-drug interactions
Second 4-hour session: case-study-based, demonstrate relevance and importance of topic
to nurses
During both training sessions nurses were encouraged to reflect on their own procedure
and opportunities for improvement
Those nurses that received this intervention were asked to identify potential medication-
related problem and highlight these to the consulting physician
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Outcomes Assessed at 0, 6, 12 months
Hospital admissions (hospital days)
Mortality
Health-related Quality of Life (15D)
Medication appropriateness (composite of Beers criteria, Anticholinergic Risk Scale, >
2 psychotropic medications, NSAIDs and proton pump inhibitors)
Not used in this review:
Cognitive assessment (MMSE)
Nutritional assessment (Mini-nutritional assessment)
Notes [author contacted]
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number generator
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Outcomes not likely to be influenced by
lack of blinding
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Reasons and proportions for attrition doc-
umented and similar in intervention and
control. Described as intention-to-treat
analysis by authors Overall attrition rate
relatively high (27.8%)
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Reasons and proportions for attrition doc-
umented and similar in intervention and
control. Described as modified intention-
to-treat analysis by authors Overall attri-
tion rate relatively high (27.8%)
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
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Similar baseline outcome measurements Unclear risk LowerHRQoL in intervention group (15D
score mean 0.61 [SD 0.12] vs 0.66 [0.11])
and higher mean number of harmful med-
ications (2.9 [SD 1.8] vs 2.5 [SD 1.7]).
Analyses were adjusted for these differences
Similar baseline characteristics Unclear risk More males (34.7% vs 22.9%), higher
prevalence of ‘as-needed’medication (mean
3.6 [SD 2.3] vs 2.9 [SD2.0]), and higher
number of comorbidities (Mean Charlson’s
index 3.2 [2.0] vs 2.5 [1.8]) in intervention
group. Analyses were adjusted for these dif-
ferences
Reliable primary outcome measure Low risk Well-defined potentially harmful medica-
tion use
Adequate protection against contamina-
tion
Unclear risk Cluster design. However, it was theoreti-
cally possible that some nurses may have
moved between intervention and control
nursing homes, although this was deemed
unlikely by the author [author contacted]
Other bias Low risk Appears to be free from other sources of
bias
Roberts 2001
Methods Cluster-RCT (randomised by care home)
Total study duration: Two years
Participants 3230 residents (905 intervention, 13 homes); 2325 control, 39 homes)
Setting: Nursing homes
Age:
Intervention < 60 2.0%, 60-69 6.6%, 70-79 21.9%, 80-89 47.4%, 90-99 20.7%, ≥
100 1.7%
Control < 60 2.6%, 60-69 5.4%, 70-79 22.3%, 80-89 46.7%, 90-99 21.1%, ≥ 100 1.
6%
Gender: Not reported
Country: Australia
Date of Study: Not reported
Interventions Three-phase intervention: introducing a new professional role to stakeholders with re-
lationship-building; nurse education; and medication review by pharmacists
The clinical pharmacy service model introduced to each nursing home was supported
with activities such as focus groups facilitated by a research nurse, written and telephone
communication, and face-to-face professional contact between nursing home staff and
clinical pharmacists on issues such as drug policy and specific resident problems, to-
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Roberts 2001 (Continued)
gether with education and medication review by pharmacists holding a postgraduate
diploma in clinical pharmacy. This was a multifaceted intervention directly targeting
nursing homes. Most of the contact with GPs was indirect, using the existing relation-
ships between nursing homes and visiting GPs. A number of focus groups and personal
interviews about the project were conducted with GPs. In intervention homes, problem-
based education sessions (6 ± 9 seminars totaling approximately 11 h per home) were
provided to nurses. Sessions addressed basic geriatric pharmacology and some common
problems in long-term care (depression, delirium and dementia, incontinence, falls, sleep
disorders, constipation and pain). Sessions were supported by wall charts, bulletins, tele-
phone calls and clinical pharmacy visits, averaging 26 h contact per home over the study.
Written, referenced drug regimen reviews were prepared by the clinical pharmacists for
500 individual residents selected by the nursing home staff. The reviews highlighted the
potential for: (1) adverse drug effects, (2) ceasing one or more drugs, (3) adding drugs,
(4) better use of specific drug therapy, particularly psychoactive drugs, (5) non drug
interventions, and (6) adverse effect and drug response monitoring. Initial reports (61%
of total) were audited by a geriatrician before dissemination. Reports were placed in
each resident’s nursing home records, made available to the resident’s GP and discussed
with nursing staff. Drugs commonly targeted in reviews and education sessions included
laxatives, histamine H2-receptor antagonists, allopurinol, quinine, antibacterials, parac-
etamol, nonsteroidal anti-inflammatory drugs (NSAIDs) and psychoactive drugs
Outcomes Measured at baseline and 12 months post-intervention:
Hospital admissions (not defined)
Mortality (survival also assessed at 22 months)
Medication-related problems
Medication costs (per resident per year based on prescription claims data)
Not used for this review:
Adverse events (from incident reports)
Resident Classification Instrument (RCI)
Drug use
Notes Supported by the Commonwealth Government of Australia under the Pharmaceutical
Education Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Homes were assigned to intervention or
control by being “drawn from a hat”
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
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Roberts 2001 (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding reported
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk No blinding reported, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions to permit judgement
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Slight imbalance in mortality and hospi-
talisations at baseline; however this was ac-
counted for in the analysis
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Mortality and Resident Classification In-
strument (RCI)
Adequate protection against contamina-
tion
Unclear risk Cluster design. [Attempted to contact au-
thor for further information but no re-
sponse]
Other bias High risk Medication reviews were undertaken for a
non-random subsample of 500 residents
(total intervention residents 905) selected
by nursing staff
Strikwerda 1994
Methods RCT (randomised by GP)
Total study duration: 6 weeks
Participants 196 residents
One nursing home
Age: mean 84.5 years (59-100)
Gender: 25% male
Country: Netherlands
Date of study: 1993
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Strikwerda 1994 (Continued)
Interventions Feedback on GP prescribing from community pharmacist
Group A received usual care, group B GPs issued with a medication list used by their
patients, group C GPs received a medication list plus feedback from community phar-
macist
Outcomes Medication-related problems
Not used for this review: drug use
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Low risk Cluster design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Insufficient information to permit judge-
ment
Blinding of outcome assessment (detection
bias)
Objective outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Primary outcomes
Unclear risk Not measured in this study
Incomplete outcome data (attrition bias)
Secondary outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Unclear risk No baseline measurements of medication-
related problems
Similar baseline characteristics High risk Most baseline characteristics similar, how-
ever fewer males in group A and fewer
medicines per resident in group B
Reliable primary outcome measure Low risk Drug use
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Strikwerda 1994 (Continued)
Adequate protection against contamina-
tion
High risk Randomised by GP, however control and
intervention residents resided in the same
nursing home
Other bias Low risk Appears to be free of other sources of bias
Zermansky 2006
Methods RCT (randomised by patient)
Total study duration: 6 months
Participants 661 (331 intervention, 330 control) care home residents, 65 care homes
Setting: Nursing and residential homes for older people
Age: Intervention mean 85.3 (IQR 81-90); control mean 84.9 (IQR 80-90)
Gender: Intervention 75 (22.7%) male; control 79 (23.9%) male
Country: UK
Date of study: 2002
Interventions Medication review by a single pharmacist
A clinical medication reviewwas conducted by the study pharmacist who held a postgrad-
uate qualification in clinical pharmacy, within 28 days of randomisation. It comprised
a review of the GP clinical record and a consultation with the resident and carer. The
pharmacist formulated recommendations with the resident and carer and passed them
on a written proforma to the GP for acceptance and implementation. GP acceptance
was signified by ticking a box on the proforma. Control patients received usual GP care
Outcomes Measured at baseline and six months ± three weeks post-randomisation:
Hospital admissions (non-elective)
Mortality
Medication-related problems
Medicine costs (cost of 28 days of repeat medicines per participant)
Not used for this review:
Number of changes in medicines per participant
Number of medicines per participant
Recorded medication reviews
Falls
SMMSE
Barthel index
Number of GP consultations
Notes Funded by The Health Foundation, 90 Long Acre, London WC2 9RA (Registered
Charity Number 286967)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Patients were randomised in randomly
sized blocks of 2 to 8 patients using an algo-
rithm written in Visual Basic in Microsoft
Access
Allocation concealment (selection bias) Low risk Not reported in paper. Allocation was con-
cealed to the research pharmacist and nurse
data collector by statistician [Author con-
tacted]
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open design, no blinding attempted
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk No blinding conducted
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Noblinding conducted, however outcomes
not likely to be influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
Primary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Similar attrition in both groups with sim-
ilar reasons for dropouts. Described as in-
tention-to-treat by authors
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Similar baseline outcome measurements Low risk Similar baseline measurements for hospital
admissions and medicine costs
Similar baseline characteristics Low risk Similar baseline characteristics reported
Reliable primary outcome measure Low risk Number of changes in medication
Adequate protection against contamina-
tion
High risk Randomised by patient therefore contami-
nation possible
Other bias Unclear risk Sample size calculation indicated that 1600
residents were required, however, only 661
residents were recruited
IQR: Interquartile Range
45Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MMSE: Mini-Mental State Examination
SD: Standard Deviation
I5D: 15 Dimensional Instrument of Health-related Quality of Life
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Avorn 1992 Whole medication regime not considered (psychoactive medicines only)
Crotty 2004c Whole medication regime not considered (psychotropic and stroke medicines only)
Lapane 2011 Focus was on delirium and falls
Milos 2013 Included community-dwelling patients in addition to nursing home residents
Characteristics of ongoing studies [ordered by study ID]
Desborough ongoing
Trial name or title Multi-professional clinical medication reviews in care homes for the elderly: study protocol for a randomised
controlled trial with cost effectiveness analysis
Methods Cluster RCT (randomised by care home)
Total Study Duration: 12 months
Participants Residents of 30 care homes for older people (average age > 65)
Interventions Intervention homes will receive a multi-professional medication review at baseline and at 6 months, with
follow-up at 12 months. Control homes will receive usual care (support they currently receive from the
National Health Service), with data collection at baseline and 12 months
Outcomes Emergency hospital admissions and Accident and Emergency (A&E) visits (number of admissions in six
months per patient)
Mortality
Potentially inappropriate prescribing (number of drugs whichmatch the STOPPcriteria at each data collection
point)
Medication costs (mean drug costs per patient - net ingredient costs for 28 days)
Not used for this review:
Number of falls (mean per patient per month)
Utilisation of primary care, secondary care and personal social services health professional time (GP, nurse
and other)
Starting date 2011
Contact information
46Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Desborough ongoing (Continued)
Notes
NCT02238652
Trial name or title Improving quality of life in nursing home residents: a cluster randomized clinical trial of efficacy (KOSMOS)
Methods Cluster RCT (randomised by care home)
Total Study Duration: ~ 16 months
Participants Residents of 38 care homes (~ 310 participants, average age > 65)
Interventions Staff training, study guidelines and manuals
Outcomes Potentially inappropriate prescribing (number of drugs which match the STOPP criteria at each collection
point)
Medications which should be introduced (assessed using the START criteria)
Hospital admissions
Mortality
Quality of life in late-stage dementia
Neuropsychiatric inventory
Activities of daily living
Starting date 2014
Contact information
Notes
Wouters ongoing
Trial name or title Discontinuing inappropriate medication in nursing home residents (DIM-NHR Study): protocol of a cluster
randomised controlled trial
Methods Cluster RCT (elderly care physicians and wards randomised)
Participants Residents of care home (~ 600 residents)
Interventions Multidisciplinary Multistep Medication Review (3MR) will be carried out by elderly care physicians in
collaboration with a pharmacist. Data will be collected at baseline and 4 months after the 3MR has taken
place
Outcomes Discontinuation of inappropriate medication (according to the STOPP criteria)
Starting new medication (according to the START criteria)
Harm (includingmortality, falls, gastrointestinal bleeding, A&Eandoutpatient visits, physician consultations)
Quality of life (measured with Dementia Quality of Life Instrument (DQI) and EQ-5D-3L
Cognitive function measured using the Severe Impairment Battery (SIB) and the Mini-Mental State Exami-
nation (MMSE)
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Wouters ongoing (Continued)
Expenditure on healthcare taking into account salary costs, medication costs, laboratory examinations,addi-
tional costs
Starting date 2014
Contact information
Notes
EQ-5D-3L: EuroQol 5 Dimension Health-related Quality of Life
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study,Country, Design Participants Intervention Outcome measures Duration
Claesson 1998
Sweden
Cluster-RCT
1854 residents in 33
nursing homes
Multidisciplinary
meetings with physician,
pharmacist and nurse(s)
Medication-related
problems
14 months
Connolly 2015
Australia
Cluster-RCT
1998 residents in 36
nursing homes
Multidisciplinary meet-
ings with study geriatri-
cian, a GP, a pharma-
cist and a nurse manager.
Education of nurses and
care-givers
Hospital admissions
Mortality
14 months
Crotty 2004a
Australia
Cluster-RCT
154 residents in 10 nurs-
ing homes
Multidisciplinary case
conferencing with GP, a
geriatrician, a pharma-
cist, residential care staff
and an Alzheimer’s Asso-
ciation representative
Medication
Appropriateness Index
3 months
Crotty 2004b
Australia
Patient-RCT
110 patients discharged
to 85 long-term care fa-
cilities
Pharmacist
transition co-ordinator.
Transfer of medicines
information to nursing
staff, family physician
and community phar-
macist plus medication
review and case confer-
encing
Adverse drug events
Hospital admissions
Medication-related
problems
Medication
Appropriateness Index
8 weeks
Frankenthal 2014
Israel
Patient-RCT
359 residents in 1
chronic care geriatric fa-
cility
Medication review by
the study pharmacist
Hospital admissions
Mortality
Quality of life
Medication appropriate-
ness (STOPP-START)
Medication-related
problems
Medicine costs
12 months
Furniss 2000
UK
Cluster-RCT
330 residents in 14 nurs-
ing homes
Medication review by a
single pharmacist
Hospital admissions
Mortality
Medication-related
8 months
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Table 1. Summary of study characteristics (Continued)
problems
Medicine costs
Garcia-Gollarte 2014
Spain
Cluster-RCT
716 residents in 36 nurs-
ing homes
Physician educational
programme followed by
on-de-
mand support (prescrip-
tion advice) by phone
Hospital admissions (to-
tal number of days spent
in hospital)
Medication appropriate-
ness (STOPP-START)
6 months
Gurwitz 2008
USA/Canada
Cluster-RCT
1118 residents in 29
units in 2 long-term care
facilities
Computerised provider
order entry with clinical
decision support
Adverse drug events 12 months
Pitkala 2014
Finland
Cluster-RCT
227 residents in 20 as-
sisted living facilities
Nurse training and edu-
cation
Hospital admissions
Mortality
Health-related Quality
of Life
Medication appropriate-
ness (Beer’s criteria plus
others)
12 months
Roberts 2001
Australia
Cluster-RCT
3230 residents in 52
nursing homes
Introductionof newpro-
fessional role, nurse ed-
ucation and medication
review by pharmacists
Hospital admissions
Mortality
Medication-related
problems
Medicine costs
24 months
Strikwerda 1994
Netherlands
Cluster-RCT
196 residents in 1 nurs-
ing home
Feedback on GP pre-
scribing from commu-
nity pharmacist
Medication-related
problems
6 weeks
Zermansky 2006
UK
Patient-RCT
661 residents in 65 care
homes
Medication review by a
single pharmacist
Hospital admissions
Mortality
Medication-related
problems
Medicine costs
6 months
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A P P E N D I C E S
Appendix 1. Electronic database search strategies
MEDLINE OvidSP 1 January 2012 - 14 May 2015
1 polypharmacy/ 2628
2 polypharm*.ti,ab. 3944
3 ((multi-drug* or multidrug*) adj2 (therapy or therapies or pre-
scribing or treatment or regime*)).ti,ab
3371
4 (beer* adj1 criter*).ti,ab. 304
5 inappropriate prescribing/ 1037
6 ((appropriate or optim* or inappropriat* or suboptim* or sub-
optim* or unnecessary or incorrect* or in-correct* or excessive
or multiple or concurrent*) adj2 (medicine? or medication? or
prescription* or drug*)).ti,ab
21359
7 ((over adj1 prescript*) or (overprescrib* or overprescript*)).ti,
ab
751
8 ((under adj prescript*) or (underprescrib* or underprescript*))
.ti,ab
276
9 medication appropriateness index.ti,ab. 72
10 (quality adj (prescribing or prescription? or medication?)).ti,ab 85
11 (improv* adj (prescrib* or prescription? or pharmaco*)).ti,ab 2066
12 case conferencing.ti,ab. 47
13 medication therapy management/ 790
14 (medication? management or medication? therapy manage-
ment ormedication? strategy ormedication? strategies or (med-
ication? adj2 review*)).ti,ab
3596
15 drug regimen review*.ti,ab. 54
16 drug utilization review/ 3215
17 (drug adj utili?ation adj2 (review* or evaluat*)).ti,ab. 413
18 drug related problem?.ti,ab. 941
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(Continued)
19 ((prescribing or prescription?) adj2 pattern?).ti,ab. 2948
20 assessing care of vulnerable elders.ti,ab. 56
21 acove.ti,ab. 46
22 stopp.ti,ab. 132
23 start screening tool.ti,ab. 18
24 screening tool of older person’s prescriptions.ti,ab. 30
25 screening tool to alert doctors to right treatment.ti,ab. 29
26 medication errors/ 10732
27 (pharmaceutical? or pharmacist? or prescrib*).ti,ab. 185124
28 pharmaceutical preparations/ 43774
29 pharmacists/ 11288
30 pharmacists’ aides/ 532
31 prescription drugs/ 3360
32 drug prescriptions/ 22654
33 prescriptions/ 2033
34 pharmaceutical services/ 4377
35 drug toxicity/ 22441
36 pharmacotherap*.ti,ab. 24486
37 drug therapy/ 28413
38 drug monitoring/ 15022
39 or/1-38 345099
40 homes for the aged/ or “homes for the aged”.tw. 11571
41 exp nursing homes/ or nursing home?.tw. 40611
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(Continued)
42 (aged adj2 (care or nursing or healthcare or residential) adj2
(facility or facilities or home?)).ti,ab
708
43 ((geriatric or elderly) adj2 (facility or facilities or care home?))
.ti,ab
354
44 hospitals, veterans/ 5928
45 or/40-44 50940
46 ((care or convalescent) adj (home? or center? or centre? or fa-
cility or facilities)).ti,ab
35311
47 ((skilled or intermediate) adj (nursing facility or nursing facil-
ities)).ti,ab
1609
48 (resident* adj2 (care or facility or facilities)).ti,ab. 6401
49 ((nursing or group or residential) adj home?).ti,ab. 24170
50 long-term care/ 22277
51 ((longterm or long term) adj3 (care or facility or facilities)).ti,
ab
18133
52 (healthcare adj2 (facility or facilities)).ti,ab. 2669
53 residential facilities/ 4759
54 assisted living facilities/ 968
55 assisted living.ti,ab. 1455
56 halfway houses/ 1025
57 or/46-56 94250
58 exp aged/ 2433322
59 geriatrics/ 26942
60 (gerontol* or ageing or aging or elder* or geriatric* or seniors
or old age or older or late* life).ti,ab
583360
61 (older adj (person* or people or adult* or patient* or inpatient*
or outpatient*)).ti,ab
85641
62 veterans/ 10381
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(Continued)
63 veteran*.ti,ab. 23572
64 or/58-63 2740961
65 exp randomized controlled trial/ 394909
66 controlled clinical trial.pt. 89435
67 randomi#ed.ti,ab. 408930
68 placebo.ab. 162358
69 drug therapy.fs. 1771119
70 randomly.ti,ab. 231035
71 trial.ab. 331228
72 groups.ab. 1449417
73 or/65-72 3543651
74 exp animals/ not humans/ 4037906
75 73 not 74 3046430
76 39 and 45 2952
77 39 and 57 and 64 2794
78 or/76-77 4142
79 75 and 78 1720
80 limit 79 to yr=“2012 -Current” 393
Embase OvidSP 1 January 2012 - 14 May 2015
1 polypharmacy/ 8098
2 polypharm*.ti,ab. 5772
3 ((multi-drug* or multidrug*) adj2 (therapy or therapies or pre-
scribing or treatment or regime*)).ti,ab
3393
4 (beer* adj1 criter*).ti,ab. 550
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(Continued)
5 inappropriate prescribing/ 1682
6 ((appropriate or optim* or inappropriat* or suboptim* or sub-
optim* or unnecessary or incorrect* or in-correct* or excessive
or multiple or concurrent* or adverse) adj2 (medicine? or med-
ication? or prescription* or prescrib* or drug*)).ti,ab
50332
7 ((over adj1 prescript*) or (over adj1 prescrib*) or (overprescrib*
or overprescript*)).ti,ab
1348
8 ((under adj prescript*) or (under adj prescrib*) or (underpre-
scrib* or underprescript*)).ti,ab
563
9 medication appropriateness index/ or medication appropriate-
ness index.ti,ab
113
10 (quality adj (prescribing or prescription? or medication?)).ti,ab 128
11 (improv* adj (prescrib* or prescription? or pharmaco*)).ti,ab 2583
12 case conferencing.ti,ab. 57
13 medication therapy management/ 4106
14 (medication? management or medication? therapy manage-
ment or drug therapy management or medication? strategy or
medication? strategies or (medication? adj2 review*)).ti,ab
6098
15 drug regimen review*.ti,ab. 61
16 (drug adj utili?ation adj2 (review* or evaluat*)).ti,ab. 441
17 drug utilization/ 14141
18 ((drug or medication) adj related problem?).ti,ab. 1973
19 ((prescribing or prescription?) adj2 pattern?).ti,ab. 4150
20 assessing care of vulnerable elders.ti,ab. 72
21 assessing care of vulnerable elders.mp. 74
22 “assessing care of vulnerable elders”/ 2
23 acove.ti,ab. 89
24 stopp.ti,ab. 349
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(Continued)
25 start screening tool.ti,ab. 46
26 screening tool of older person’s prescriptions.ti,ab. 63
27 screening tool to alert doctors to right treatment.ti,ab. 56
28 medication error/ 11886
29 (pharmaceutical? or pharmacist? or prescrib*).ti,ab. 264124
30 drug/ 19225
31 pharmacist/ or pharmacy technician/ 45126
32 prescription drug/ 4573
33 prescription/ 106402
34 pharmacy/ 45688
35 pharmacotherap*.ti,ab. 31782
36 exp drug therapy/ 1368324
37 drug monitoring/ 26385
38 drug toxicity/ 6318
39 “drug use”/ 72662
40 or/1-39 1750098
41 home for the aged/ or “home? for the aged”.ti,ab. 5316
42 ((care or convalescent) adj (home? or center? or centre? or fa-
cility or facilities)).ti,ab
39224
43 public hospital/ 21393
44 exp nursing homes/ 26353
45 ((skilled or intermediate) adj (nursing facility or nursing facil-
ities*)).ti,ab
1724
46 ((aged or geriatric or elderly) adj2 (care home? or facility or
facilities or residential)).ti,ab
1272
56Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
47 or/41-46 86634
48 (resident* adj2 (care or facilit*)).ti,ab. 6772
49 ((nursing or group or residential) adj home*).ti,ab. 21258
50 long term care/ 83653
51 ((longterm or long term) adj3 (care or facilit*)).ti,ab. 17973
52 residential home/ 3955
53 residential home*.ti,ab. 707
54 assisted living facility/ 1431
55 assisted living.ti,ab. 1711
56 (life care cent* or continued care cent* or extended care facilit*)
.ti,ab
283
57 halfway house/ 351
58 or/48-57 118205
59 exp aged/ 1646752
60 geriatrics/ 15941
61 (aged or elder* or geriatric* or seniors or old age or older or
late* life).ti,ab
799481
62 (old* adj (person* or people or adult* or patient* or inpatient*
or outpatient*)).ti,ab
126453
63 veteran/ 11947
64 veteran*.ti,ab. 22983
65 or/59-64 2164247
66 clinical trial/ 696973
67 randomized controlled trial/ 324874
68 randomization/ 57914
69 single blind procedure/ 18802
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(Continued)
70 double blind procedure/ 96148
71 crossover procedure/ 38442
72 randomi?ed controlled trial*.ti,ab. 112095
73 rct.tw. 16460
74 random allocation.ti,ab. 1121
75 randomly allocated.ti,ab. 18340
76 allocated randomly.ti,ab. 1382
77 (allocated adj2 random).ti,ab. 292
78 single blind*.ti,ab. 12471
79 double blind*.ti,ab. 109011
80 ((treble or triple) adj2 blind*).ti,ab. 426
81 prospective study/ 267926
82 or/66-81 1145782
83 exp animal/ not human/ 2195026
84 82 not 83 1107995
85 40 and 47 13171
86 40 and 58 and 65 10550
87 or/85-86 20859
88 84 and 87 4153
89 limit 88 to yr=“2012 -Current” 989
Cochrane Central Register of Controlled Trials (CENTRAL) Wiley 1 January 2012 - 14 May 2015
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#1 [mh ˆpolypharmacy] 101
#2 (polypharm*):ti,ab,kw 273
#3 (multi-drug* or multidrug*) near/2 (therapy or therapies or
prescribing or treatment or regime*):ti,ab,kw
331
#4 (beer near/2 criter*):ti,ab,kw 3
#5 [mh ˆ“inappropriate prescribing”] 49
#6 (appropriate or optim* or inappropriat* or suboptim* or sub-
optim* or unnecessary or incorrect* or in-correct* or excessive
or multiple or concurrent*) near/2 (medicine* or medication*
or prescription* or drug*):ti,ab,kw
2588
#7 (over near/1 prescript*) or (overprescrib* or overprescript*):ti,
ab,kw
62
#8 (under near/1 prescript*) or (underprescrib* or underpre-
script*):ti,ab,kw
16
#9 medication appropriateness index:ti,ab,kw 20
#10 (quality near/1 (prescribing or prescription* or medication*))
:ti,ab,kw
59
#11 (improv* near/1 (prescrib* or prescription* or pharmaco*)):ti,
ab,kw
189
#12 case conferencing:ti,ab,kw 12
#13 [mh ˆ“medication therapy management”] 53
#14 medication* management:ti,ab,kw or “medication* therapy
management”:ti,ab,kw or “medication* strategy”:ti,ab,kw or
“medication* strategies”:ti,ab,kw or (medication* near/2 re-
view*):ti,ab,kw
611
#15 drug regimen review*:ti,ab,kw or (drug near/1 utili?ation near/
2 (review* or evaluat*)):ti,ab,kw
153
#16 [mh ˆ“drug utilization review”] 123
#17 drug related problem*:ti,ab,kw or (prescription* near/2 pat-
tern*):ti,ab,kw or “assessing care of vulnerable elders”:ti,ab,kw
or (acove):ti,ab,kw or (stopp):ti,ab,kw
194
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(Continued)
#18 start screening tool:ti,ab,kw or “screening tool of older person’s
prescriptions”:ti,ab,kw or “screening tool to alert doctors to
right treatment”:ti,ab,kw
3
#19 [mh ˆ“medication errors”] 230
#20 (pharmaceutical* or pharmacist* or prescrib*):ti,ab,kw 15159
#21 [mh ˆ“pharmaceutical preparations”] 229
#22 [mh ˆpharmacists] 452
#23 [mh ˆ“pharmacists’ aides”] 8
#24 [mh ˆ“prescription drugs”] 92
#25 [mh ˆ“drug prescriptions”] 471
#26 [mh ˆprescriptions] 91
#27 [mh ˆ“pharmaceutical services”] 133
#28 [mh ˆ“drug toxicity”] 780
#29 (pharmacotherap*):ti,ab,kw 5106
#30 [mh ˆ“drug therapy”] 434
#31 [mh ˆ“drug monitoring”] 1129
#32 {or #1-#31} 25427
#33 [mh “homes for the aged”] 498
#34 home* for the aged:ti,ab,kw or (aged near/2 (care or nursing or
healthcare or residential) near/2 (facility or facilities or home*)
):ti,ab,kw or (geriatric or elderly) near/2 (facility or facilities
or care home*):ti,ab,kw
990
#35 [mh “nursing homes”] 1057
#36 [mh ˆ“hospitals, veterans”] 293
#37 {or #33-#36} 1826
#38 (care or convalescent) next (home or homes or center* or cen-
tre* or facility or facilities):ti,ab,kw
3372
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#39 ((skilled or intermediate) near/2 (nursing facility or nursing
facilities)):ti,ab,kw
108
#40 (resident* near/2 (care or facility or facilities)):ti,ab,kw 678
#41 (nursing or group or residential) next (home or homes):ti,ab,
kw
2301
#42 (longterm or long term) near/3 (care or facility or facilities):ti,
ab,kw
3110
#43 [mh ˆ“long-term care”] 1115
#44 [mh ˆ“residential facilities”] 148
#45 (assisted living):ti,ab,kw 315
#46 [mh ˆ“halfway houses”] 18
#47 {or #38-#46} 8636
#48 [mh aged] 997
#49 [mh ˆgeriatrics] 202
#50 (gerontol* or ageing or aging or elder* or geriatric* or seniors
or old age or older or late* life):ti,ab,kw
44963
#51 (older next (person* or people or adult* or patient* or inpa-
tient* or outpatient*)):ti,ab,kw
7601
#52 [mh veterans] 488
#53 (veteran*):ti,ab,kw 2478
#54 {or #48-#53} 47508
#55 #47 and #54 2330
#56 #32 and (#37 or #55) Publication Year from 2012 to 2015 83
CINAHL EbscoHost 1 January 2012 - 14 May 2015
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S1 MH polypharmacy 1,698
S2 polypharmacy 2,183
S3 beer* n1 criter* 150
S4 ((appropriate or optim* or inappropriat* or suboptim* or sub-
optim* or unnecessary or incorrect* or in-correct* or excessive
or multiple or concurrent*) n2 (medicine? or medication? or
prescription* or drug*))
6,010
S5 (over n2 prescript*) or overprescrib* or overprescript* 420
S6 ”under prescript*“ or underprescrib* or underprescript 54
S7 ”medication appropriateness index*“ 24
S8 quality n2 (prescri* or medication*) 424
S9 improv* n2 (prescri* or pharmaco*) 959
S10 ”assessing care of vulnerable elders“ 37
S11 acove 24
S12 ((multi-drug* or multidrug*) n3 (therapy or therapies or pre-
scribing or treatment or regime*))
587
S13 MH medication errors 8,551
S14 MH inappropriate prescribing 353
S15 pharmaceutical* or prescribing 25,134
S16 MH pharmacists 4,753
S17 MH ”pharmacy technicians“ 205
S18 MH ”drugs, prescription“ 10,395
S19 MH ”prescriptions, drug” 4,242
S20 MH “pharmacy service”) or (MH “pharmaceutical care”) 2,710
S21 pharmacist* 7,487
S22 (MH “medication management (iowa nic)”) or (MH “medi-
cation managements (iowa nic) (non-cinahl)”)
2
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(Continued)
S23 MH drug toxicity 3,066
S24 stopp or start screening tool 46
S25 “screening tool of older person’s prescriptions” 7
S26 “screening tool to alert doctors to right treatment” 8
S27 (medication* n2 (management or review* or strateg*)) 2,550
S28 pharmacotherap* 3,689
S29 (MH “drug therapy”) 6,126
S30 (MH “drug utilization”) 3,823
S31 “drug utili*ation” n2 (review* or evaluat*) 216
S32 MH drug monitoring 3,766
S33 “drug regimen review*” 11
S34 “case conferencing” 21
S35 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR
S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR
S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR
S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30 OR S31 OR S32 OR S33 OR S34
74,621
S36 “homes for the aged” or MH housing for the elderly 1,945
S37 MH nursing homes+ or mw nursing home 33,249
S38 (aged n2 (“care facilit*” or “care home*” or “nursing facilit*”
or “residential facilit*”)) or “aged nursing home*” or (aged n1
“healthcare facilit*”)
472
S39 “aged residential home*” or (geriatric n2 facilit*) or (geriatric*
n1 “care home*”) or (elderly n2 (facilit* or “care home*”))
284
S40 (MH “hospitals, veterans”) 3,243
S41 S36 OR S37 OR S38 OR S39 OR S40 38,021
S42 ((care or convalescent) w1 (home* or center* or centre* or
facilit*))
21,905
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S43 ((skilled or intermediate) w1 “nursing facilit*”) 2,493
S44 (resident* n2 (care or facilit*)) 10,260
S45 ((nursing or group or residential) n1 home*) 36,410
S46 ((longterm or long term or long-term) n3 (care or facilit*)) 22,339
S47 MH residential facilities or MH long term care 19,412
S48 “residential home*” or healthcare n2 facilit* 1,436
S49 MH assisted living 2,010
S50 “assisted living” 2,521
S51 “life care cent*” or “continued care cent*” or “extended care
facilit*”
152
S52 (MH “halfway houses”) 97
S53 S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR
S49 OR S50 OR S51 OR S52
75,485
S54 (MH “aged+”) 355,481
S55 MH geriatrics 2,639
S56 ageing or aging or gerontol* or elder* or geriatric* or seniors
or “old age” or “late* life”
142,501
S57 old* n1 (person* or people or adult* or patient* or inpatient*
or outpatient*)
47,396
S58 MH veterans 7,376
S59 veterans 13,892
S60 S54 OR S55 OR S56 OR S57 OR S58 OR S59 408,165
S61 (MH “clinical trials”) 81,870
S62 PT clinical trial 52,097
S63 TX clinic* n1 trial* 121,846
S64 TX ((singl* or doubl* or tripl* or trebl*) n1 (blind* or mask*)
)
640,410
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S65 TX “randomi* control* trial*” 52,249
S66 MH random assignment 32,044
S67 TX “random* allocat*” 2,772
S68 MH quantitative studies 10,797
S69 TX “allocat* random*” 135
S70 S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR
S68 OR S69
767,987
S71 (MH “animals+”) not MH human 28,052
S72 s70 not s71 764,290
S73 S35 AND S41 1,524
S74 S35 AND S53 AND S60 1,530
S75 S73 OR S74 2,131
S76 S72 AND S75 543
S77 s76 Limiters - Published Date: 20120101-20151231 133
Appendix 2. Trial registry search strategies
ClinicalTrials.gov, US National Institutes of Health (NIH) searched 18 May 2015
( residential homes OR nursing homes ) AND ( medicine OR
medication OR prescription OR drug ) AND ( elderly OR old
OR aged ) AND ( randomly OR random OR randomised OR
randomized OR RCT )
78
International Clinical Trials Registry Platform (ICTRP), World Health Organization (WHO)
Number of results: 11
Each term 1 was searched with each possible combination of the other terms (2-4). Terms were combined using AND
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Term 1 Term 2 Term 3 Term 4
Randomised Nursinghomes elderly drugs
Randomized Residentialhomes old medication
RCT pharmacy
Randomly polypharmacy
WH A T ’ S N E W
Last assessed as up-to-date: 14 May 2015.
Date Event Description
10 August 2015 New citation required but conclusions have not changed The authorship of the review has changed. This review
includes 12 studies
14 May 2015 New search has been performed New searches performed to May 14, 2015. Four new
studies identified
H I S T O R Y
Protocol first published: Issue 4, 2011
Review first published: Issue 2, 2013
Date Event Description
22 February 2013 Amended Minor edits - listing of 2 excluded studies
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Medical Subject Headings (MeSH)
∗Homes for the Aged; ∗Nursing Homes; Drug Prescriptions [∗standards]; Inappropriate Prescribing [∗prevention & control]; Medica-
tion Reconciliation; Quality Improvement [∗standards]; Randomized Controlled Trials as Topic
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MeSH check words
Aged; Humans
68Interventions to optimise prescribing for older people in care homes (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
